Perspectives on participation in dementia prevention clinical trials by Akenine, Ulrika
From THE DEPARTMENT OF NEUROBIOLOGY, CARE 
SCIENCE AND SOCIETY 
Karolinska Institutet, Stockholm, Sweden 
PERSPECTIVES ON PARTICIPATION IN 








“Leap of faith, 2018” – into the unknown… 
Printed with the permission from the artist 
ERIK JOHANSSON – SURREAL PHOTOGRAPHY 
www.erikjo.com 
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Click to enter Name of Printer 
© Ulrika Akenine, 2021 
ISBN 978-91-8016-159-6 
 
PERSPECTIVES ON PARTICIPATION IN DEMENTIA PREVENTION  
CLINICAL TRIALS 




Professor Miia Kivipelto 
Karolinska Institutet 
Department of Neurobiology, Care Sciences and 
Society 
Division of Clinical Geriatrics 
 
Co-supervisor(s): 
Associate Professor Alina Solomon 
University of Eastern Finland 
Institute of Clinical Medicine/Neurology 
Division of Clinical Research Centre 
 
Dr. Mandana Fallah Pour 
Karolinska Institutet 
Department of Neurobiology, 
Care Sciences and Society 
Division of Occupational Therapy 
Opponent: 
Associate professor Dag Nyholm 
Uppsala University 
Department of Neuroscience 
Division of Neurology 
 
Examination Board: 
Professor Ingrid Hellström 
Ersta Sköndal Bräcke University College 
Department of Health Care Sciences 
 
Professor Pernilla Hillerås 
Red Cross University College 
Sophiahemmet University 
Karolinska Institutet 
Department of Neurobiology, Care Sciences and 
Society 
 
Professor Ulrica Nilsson 
Karolinska Institutet 
Department of Neurobiology, Care Sciences and 
Society 












Dementia is an enormous global health challenge with a rapid increase in the number of 
people affected. There is an urgent need for research to find effective treatments and 
preventive strategies. Dementia prevention research is undergoing rapid development with 
novel approaches and techniques used. Both pharmacological and multimodal lifestyle 
randomized controlled trials (RCTs) have become longer, more complex, and target people 
earlier in the disease continuum. For the participants in clinical trials, this means new 
challenges.  
The overall aim of this thesis was to explore the experiences of participation in dementia 
prevention clinical trials among study participants, study partners, and specialized 
personnel/ staff. Furthermore, the aim was to further understand their attitudes and 
knowledge about dementia and related diagnoses. All studies used qualitative method. Data 
from different kind of RCTs was collected with questionnaires including open-ended 
questions, focus groups and individual interviews. Content analysis and Grounded theory 
were used.   
 
Study I Questionnaire with open-ended questions to 19 participants and 20 study partners 
in immunotherapy Alzheimer´s disease (AD) phase I-II RCTs and group interview with 
eight staff members in the clinical trial unit were used. Staff members highlighted the high 
burden for the participants. The main motives for participation were a willingness to help 
research and the benefits of access to specialized care. The main disadvantages were that 
participating was time-consuming and perceived distress in connection to some 
investigations.  
Study II Focus group interviews were conducted within the Healthy Ageing Through 
Internet Counselling in the Elderly (HATICE) study with expert nurses (n=13) in 
cardiovascular disease (CVD) prevention in Finland and in the Netherlands. The purpose 
was to describe nurses' best experiences and practices with supporting CVD prevention and 
describe their suggestions on how to integrate their experiences into an online eHealth 
platform. Important aspects were to establish a relationship of trust, awareness and 
expectation management, and appropriate time and monitoring.  
Study III Focus groups interviews with older “at risk” adults (presence of CVD risk 
factors) in Finland, The Netherlands, and France were conducted as part of the HATICE 
study (n=44). The purpose was to explore attitudes of older adults at increased risk of CVD 
and dementia and engagement in an eHealth self-management prevention program as well 
as facilitators and barriers. The results were represented in three categories: access to 
reliable information about CVD and dementia, trust in the healthcare provider, and burden 
and stigma of dementia.  
Study IV Individual interviews with participants in multimodal dementia prevention 
MIND-ADMINI trial among persons with prodromal AD (n=8) were conducted. The 
participants' experience of participating in the trial is presented as a dynamic process. 
Previous knowledge, their motives, and the received information guide the participants' 
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decision to take part in the trial. The trial was well tolerated and received even though the 
participants initially experienced high burden and difficulties managing information 
provided.  
 
Conclusions: Despite differences in the trials and target populations, the participants 
presented similar motives for participating in dementia prevention trials including altruistic, 
hope for personal benefits of the interventions, and access to specialized care. There are 
differences in the participants' preferences and need for support in a trial, between the 
participating countries, and along the disease continuum. To address this, a more person-
centred approach in the conduction of the trials is suggested. This may improve 
participant´s situation and the quality of RCTs which is important given the increasing 
complexity and new methods used in dementia prevention trials. 
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This thesis is written in this context of the rapid development and of dementia prevention and 
risk reduction research and randomized controlled trials (RCT) trials, providing participants, 
study-partners, and specialized personnel perspectives on participating in trials in different 
settings. Dementia caused by Alzheimer's disease (AD) was, until 1970, regarded as 
untreatable. After discovering cholinergic deficiency in the cortex of AD patients, a number of 
RCTs aimed at increasing acetylcholine levels. The first cholinesterase inhibitors were 
introduced in the market in the mid-1990s. These symptomatic drugs are still used and are the 
main treatments options for AD together with NMDA receptor antagonist (1). Ethical issues 
discussed at this time around 1980, were disclosure of the diagnose to the person affected, the 
use of placebo in clinical trials, and patients' competency to consent to research (2). In the 
search for disease-modifying therapies, several drugs have been tested in RCTs during the last 
decades with no or limited success (3). During the last decade, there has been positive signals 
and increasing interest for non-pharmacological interventions to prevent or postpone the onset 
of dementia (4). Since then, new diagnostic criteria, primarily developed for research (5), has 
made it possible to target more early phases of AD  with different interventions. The knowledge 
about AD is continuously developing (6), and the disease is now considered as a biological 
entity having a preclinical, prodromal, and dementia phase (7). However, this development is 
followed by new ethical issues, such as disclosure of AD diagnosis to asymptomatic or 
minimally symptomatic persons, the uncertainty of biomarker-based diagnoses, and social 
stigma in AD and dementia (8). In many non-pharmacological interventions, the target 
population is “at-risk” general population, eg, earlier and broader than the specific AD research 
criteria.  
Disease-modifying therapies (DMTs) aim to prevent or delay the onset or progression of 
cognitive impairment. DMTs with different approaches (e.g. targeting amyloid and, tau, 
neuroprotection, anti-inflammatory, and metabolic interventions) have been tested in several 
pharmacological phase III studies, but they have failed to achieve clinical endpoints (9).  
Biomarkers such as advanced brain imaging, results from cerebrospinal fluid (CSF) testing, 
and genetic testing,  play an increasingly important role in AD drug development (10), and is 
also important for an earlier and more accurate diagnosis. The new possibilities to detect 
disease pathology in persons with very mild symptoms or even without any symptoms has 
created the target group at risk for dementia from the biomarker perspective. This has the 
potential to be helpful, but as the therapeutic paradigm shifts from symptom management to 
prevention, disclosure and communicating the meaning of biomarkers and risk prediction to 




Multidomain lifestyle interventions address the etiology of cognitive impairment, dementia, 
and AD as multifactorial and with several potentially modifiable risk factors and protective 
factors, table 1, including vascular lifestyle-related factors (13-15).  
Table 1. Proposed modifiable risk and protective factors for dementia 
 
During the last decades, there has been increasing evidence linking various modifiable risk 
factors throughout the life-course to dementia and AD (16). The recent Lancet Commission 
paper estimated that 40% of dementia globally is related to modifiable risk factors (modified 
list, see table 1).  It is important to acknowledge that the evidence level for these risk factors is 
varying. For some (e.g. vascular risk factors and physical activity),  it is already quite strong 
but for others (eg social isolation and hearing loss) it is still more limited and more studies are 
needed (17).  There are also ‘novel’ risk factors which have been getting more interest recently 
e.g. feelings of loneliness and hopelessness (not only depression), stress and sleep disturbances. 
There is also intensive research going on to analyze the possible long-term impact of covid-19 
infection for the risk of cognitive impairment and eventually dementia (18).   
Most of the evidence concerning modifiable risk factors comes from epidemiological and 
experimental studies and it has been more challenging to get evidence from RCTs. The 
previous single domain interventions targeting modifiable risk factors have yielded modest or 
negative trials (16) Multimodal prevention trials target several risk factors simultaneously for 
optimal preventive effect, e.g., exercise, nutritional guidance, cognitive training, social activity, 
and monitoring of metabolic and vascular risk factors (4). The first multidomain RCT, the 
Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability 
(FINGER), showed a beneficial effect of the intervention on the primary outcome, change in 
cognition on neuropsychological test battery (NTB) (19). The FINGER model has been 
adapted to local, geographical, ethnical, and cultural differences, and new trials have started 
Risk factors Protective factors 
Diabetes Healty Diet 
High blood pressure at mid life Education 
Obesity at midlife Physical activity 
Physical inactivity Mental activity 
Depression Social activity 
Smoking  
Low education  
Hearing loss  
Traumatic Brain Injery  
High alcohol consumption  
Social isolation  
Air pollution  










worldwide in the World-Wide FINGERS network (20). Other novel strategies in dementia 
research are, for example, preparing readiness-cohorts, adaptive designs(21), and the use of 
internet or eHealth tools for prevention trials (22, 23), which has increasing relevance in the 
current covid-19 pandemic landscape. 
When researcher and various stakeholders formulate goals for future biomedical and 
pharmaceutical research, they stress the need for a more holistic approach in dementia research, 
future directions are suggested to focus on prevention, early diagnosis, and  personalized care, 
and strong involvement of the patient and user perspective (24). Among these 
recommendations are topics concerning knowledge and awareness of  dementia/AD and risk 
reduction, including different professional stakeholders and professions in research, and a need 
to facilitate collaboration across research domains and geographical locations (25). In the 
future, dementia prevention and personalized care are suggested to work closer with the 
vascular  and other non-communicable disease (NCD) prevention field (integrated 
interventions) and public health for developing, evaluate and implementing brain health 
services (26). The interprofessional perspective are highlighted as essential in the development 
of the research field. A multiprotection aspect is present through this thesis, from the aim to 
present different perspectives form different groups, to the composition of the reseach groups, 
with a strong multi professional representation. 
The purpose with this thesis is to describe different perspectives and experiences of  dementia 
prevention clinical trials: pharmacological trials, lifestyle interventions, and the usage of new 
technology in prevention trials targeting persons at risk for developing dementia, prodromal 
AD, and mild dementia, study partners, and expert health care professionals. Knowledge about 
this different perspective can help to safeguard the wellbeing of participants in these trials. 
Furthermore, this knowledge can be helpful in design, conduction, and evaluation of dementia 




Neurocognitive disorder (NCD) is the term that is used in the latest version of the Diagnostic 
and Statistical Manual of Mental Disorders, 5th edition (DSM-5) (American Psychiatric 
Association, DSM 5) for what are used to be called dementia. The word dementia, from Latin, 
means "a being out of one's mind" is slowly replaced, but such changes take time. In this thesis, 
both terms will be used as they both are used in general population, clinical settings and in 
research. The term Dementia is still the one most used and understood by the public, patients, 
and healthcare staff, although it might be more stigmatizing than the newer term, 
Neurocognitive disorder (27). 
Historically, dementia has been considered a part of normal aging rather than a disease.  This 
reflects in the previous use of the diagnose "senile dementia" in the ninth edition of the 
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International Classification of Disease (ICD-9) used in Sweden until 1997. Even if dementia is 
primarily age related (28) several other factors contribute to the risk of developing dementia, 
including cardiovascular morbidity, psychiatric diseases, and genetic factors (29-31).  Major 
neurocognitive disorders or dementia is a syndrome diagnose for a set of symptoms where the 
cognitive impairment affects the ability to be independent in everyday activities and decline 
over time, caused by a group of neurodegenerative diseases and do not take biological 
background into account. The most common forms of dementia are AD with 60-70% of all 
cases, followed by Vascular dementia (VaD) 15%, Dementia with Lewy bodies (LBD), and 
Frontotemporal dementia (FTD) (32) (33). The primary cause of VaD is cerebrovascular 
disease with disturbed function of blood vessels in the brain by several pathologies causing 
cognitive impairment (34). 
Dementia is an enormous global health challenge. According to the World Health Organization 
(WHO) (17), this progressive syndrome characterized by severe cognition and functional 
impairment was the fifth most common overall cause of death in 2016. I the older population 
segment, it is a major cause of disability, institutionalization, and death. 
50 million people worldwide, and 9 million in Europe, are estimated to be affected by dementia. 
Within 30 years, this number is expected to double in Europa (35) and triple worldwide (36). 
This is due to an ageing population in both Western and low- and middle-income countries. 
The greatest increase in dementia cases is expected in the low- and middle-income countries. 
The World Health Organization (WHO) acknowledged this trend, sometimes described in 
terms of a fast-growing epidemic, and highlighted dementia and its prevention as a global 
public health priority (17). Alzheimer’s disease is not equal to dementia, although dementia is 
the end state of the disease that gradual progress, but starts long before clinical symptoms are 
evident (37, 38). 
Symptoms of dementia are associated with a cognitive deficit in multiple domains and 
functional deterioration in parallel with behavioral and psychological symptoms (39, 40). 
Cognitive deficits commonly affect memory functions, executive functions, learning, 
language, visuospatial functions, motor functions, and attention (29). The possibility of mixed 
etiology is well recognized (dementia neurocognitive disorder due to multiple etiologies) 
especially among the older age groups. 
2.2 COGNITIVE IMPAIRMENT 
In normal aging, some deterioration of cognitive abilities such as memory, problem solving, 
and the ability to plan and execute tasks, can be considered as normal, as well as some 
deterioration in speed and flexibility of thinking, reasoning and processing information (41). 
When the deterioration in these areas progress faster and become more severe than expected 
due to aging, it is a pathological impairment (27). 
Pathological cognitive impairment occurs when the changes are more pronounced and rapid 
than can be expected from aging alone. The most severe expression of pathological cognitive 
impairment is dementia, which is characterized by an intra-individual cognitive decline severe 
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enough to compromise functioning and cause disability. Mild cognitive impairment (MCI) is 
a term used to describe clinical state of minor impairment in one or several cognitive functions, 
while others may be unimpaired. There are multiple underlying causes of MCI and some may 
be reversable such as medication side effects or depression. However, some MCI patients may 
progress to AD and some to other dementia diagnosis while others will not decline further in 
cognition (42, 43). 
Cognitive abilities are very important for the capacity to comprehend information and make 
informed medical decision, and to understand the consequences of different decisions (44). 
Understanding, reasoning, and appreciating are essential for the ability to evaluate risk and 
benefits (45). 
2.3 ALZHEIMER´S DISEASE 
Alzheimer's disease (AD) was first described by the German psychiatrist and neuropathologist 
Alois Alzheimer after examining his patient Auguste Deter in 1901. Auguste suffered from 
progressive memory loss, disorientation, and hallucination. After her death, Dr. Alzheimer 
performed postmortem autopsy studies of her brain and described cerebral atrophy and protein 
deposits representing the classic manifestations of AD. 
AD is the most common cause of dementia. The typical disease progression is gradual over a 
long period of time, and the pathological changes in the brain may start to develop decades 
before dementia diagnosis can be made. In recent years, new methods, diagnostic tools, and 
research diagnostic criteria have been developed, including biomarkers' usage before clinical 
signs of disease appear (46). The RTCs have now shifted from later stages in the disease 
continuum towards targeting the earlier stages of preclinical or prodromal AD (47). With this 
shift in defining the disease and development of new criteria, trials for AD treatment has 
become RCTs for dementia prevention.  
AD is considered a multifactorial disease probably driven by both environmental and genetic 
factors (48). Several studies have reported an increased risk for dementia and AD in association 
with vascular, metabolic, and lifestyle-related risk factors besides age and genetic factors. 
These include e.g., obesity, hypertension, hypercholesterolemia, especially at midlife, and 
diabetes mellitus (46). Unhealthy dietary habits, smoking, alcohol drinking, and lack of 
physical activity also add to the increased dementia risk. On the other hand, an active lifestyle 
including physical, social, and cognitive activities and education have been suggested as 
protective factors (4, 49). Dementia risk scores, e.g., the CAIDE risk score (49), that combine 
several modifiable risk factors now make it possible to identify people who have an increased 
risk of developing dementia and who may benefit most from interventions targeting vascular 
lifestyle factors (4, 50).  
Today, different biomarkers are used in research and clinical settings to identify persons with 
a high risk of developing AD dementia. CSF biomarkers (low beta-amyloid, and high total tau 
and phosporilated tau levels) and neuroimaging-based biomarkers (PET, MRI) are part of the 
proposed research diagnostic criteria for AD (37, 51). The clinical use of biomarkers helps with 
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an early and more accurate diagnosis, and in research studies, biomarkers can help select the 
most suitable individuals for clinical trials. The new possibilities to detect disease pathology in 
persons with very mild symptoms (prodromal AD), or even without any symptoms (preclinical 
AD) have created the target group at risk for dementia from the biomarker perspective (47).  
 
3 DEMENTIA PREVENTION CLINICAL TRIALS 
The terms prevention and risk reduction are sometimes used interchangeably in the literature. 
WHO uses the term risk reduction in their guidelines: Risk reduction of cognitive decline and 
dementia (36)  
WHO defines the term “prevention” as "specific population and individual-based interventions 
aimed to minimize the burden of diseases and associated risk factors." (52) 
Dementia prevention RCTs may not always be easy to put in the well-recognized categories of 
primary, secondary, and tertiary preventions. Dementia primary prevention aims to reduce 
disease incidence by addressing disease mechanisms or increasing resistance to disease by 
targeting persons in the population at a time when they do not yet bear either disease markers 
or clinical impairment. Dementia secondary prevention aims to detect and target clinically 
normal individuals with biomarker evidence of disease to delay or prevent symptom onset. 
Tertiary dementia prevention aims to target patients with clinical impairment to reduce the 
impact of progressive symptomatic decline (36, 46).  
The paradigm shifts towards the recognition that neurobiology changes occur long before 
cognitive symptoms AD and the RCTs targeting the disease in earlier stages, has entailed that 
trials has become increasingly complex in design, longer and  more burdensome for 
participants. Dementia preventive trial faces many challenges, and one of the major challenges 
is selecting and recruit a target population most likely to benefit from the intervention. 
Pharmacological trials with a disease-modifying approach have failed repeatedly, targeting 
mild to moderate Alzheimer's disease. The failures in pharmacological trials has contributed to 
highlight the need of non-pharmacological approaches targeting different vascular, metabolic, 
lifestyle related, and other modifiable risk and protective factors (53). The shift to target the 
earlier stages of the diseases, has resulted in a majority of new trials are recruiting the 
participants at a pre-dementia stage (54).  
The use of biomarkers in the recruitment process is often required and the participants also 
have to fulfill certain cognitive eligibility criteria. Using biomarkers in preclinical disease 
entails ethical challenges.  A person's right to know and not know their biomarkers as they 
prefer must be ensured (55). Recruitment of the large numbers of participants is challenging 
for most trials. Even when all the inclusion criteria are met, not all possible candidates are 
willing to participate in long demanding trials. Further barriers for recruitment in  dementia 
prevention trials are  insufficient knowledge among the public about dementia and the 
possibility for prevention and perceived disease stigma (56). 
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New strategies in dementia preventive research are developed continuously. Adaptive design, 
for example, where changes can be done during the RCT, doses can be adjusted, arms with 
different interventions can be discontinued during the trial if the preliminary results is not 
satisfying, and a control group can be shared between several investigations, has been applied 
in a few studies, e.g.,  European Prevention of Alzheimer's Dementia Consortium (EPAD) (57).  
Another new strategy likely to be seen in the future is combining disease-modifying drugs with 
lifestyle interventions in RCTs and eHealth solutions. This rapid development is likely to affect 
how participation in clinical trials are experienced. Perspectives form the participants, study 
partners and personnel with hand on experiences with conduction of trials or expertise in the 
area, can have sustainable value in further development of dementia prevention reseach.  
The interest for the participants motives and experiences of taking part in clinical trial has 
increased as trials are getting longer and more complex.  To participate in long trials with many 
study visits and with intense or invasive interventions are burdensome for the participants (58). 
Motives for participating in clinical trials has been previously investigated, and altruism is the 
most common described reason for participation in trials where there is no expected benefits 
of the interventions for the participants, although further participation seems to be unlikely if 
there is no personal benefits (59-64). To be able to help others in the future, and to bring hope 
to future generations and supporting reseach was important for the participants. The feeling of 
being part of finding a solution was described by participants and care givers in qualitative 
interview and survey studies (60, 64). Other important motives for participating in a clinical 
trial were extra medical monitoring and expected health benefits from taking part in a lifestyle 
intervention trial (65). 
Many studies have described recruitment and retention of participants to dementia prevention 
trials, and described facilitators, barriers and different strategies (66-70). A survey study shows 
that recruitment may be more challenging in trials with high-burden and high-risk in MCI 
population compared to a dementia population (58). A telephone interview study among RCT 
centers in UK showed that complicated trial information constitutes a major barrier for 
recruitment to AD clinical trials and highlighted the need for clear and concise study 
information (70). Participants in a qualitative study revealed low awareness of the cause and 
risk factors of cognitive disorders and prevention (71) and to increase public awareness and 
attitudes towards research is described as essential to meet future need in participant 
recruitment of dementia RCTs (66). Some studies have investigated experiences and attitudes 
from participants in clinical trials, but many are done in hypothetical research situations.  
In many current and future trials, participants will have to learn their genetic and or biomarker 
status to be eligible for clinical trials and the risk and means of discussing genetic or biomarker 
results to participants is discussed in several studies, especially in pre-clinical or prodromal 
phases of the Alzheimer continuum (72-75). Although the ethical discussion of biomarker 
disclosure is outside the scoop of this theses, some aspects of this ethical dilemma are present 
in this project. 
 
 17 
This thesis highlights the need for more knowledge on how to increase awareness in the public, 
reduce stigma, and provide understandable information to the participants, and the need to 
adapt trial protocols to the needs of the participants. The studies provide perspectives on three 
different types of multinational dementia preventive trials: Pharmacological trials in early 
phase, eHealth trial and multimodal lifestyle trial.  
3.1 PHARMACOLOGICAL CLINICAL TRIALS 
Drug discovery is in general complicated, and especially in neuroscience, with an estimated 
failure rate greater than 95% (76). The clinical need for symptomatic and disease-modifying 
therapies (DMTs) is enormous and combined with a potentially big world market for 
pharmaceutical companies, which drives the research and development of disease treatment 
(3). In the 1980s and 1990s, the cholinergic hypothesis drove drug development and the trials 
in the search for AD therapy, even if interests in other agents such as neuroprotective, anti-
inflammatory, and nutritional, emerged in the late 1990s. Four cholinesterase inhibitors have 
been marked for AD treatment and none since 2002 in Europe. The amyloid cascade 
hypothesis, presented in 1991(77), has since dominated the field (78). The first anti-amyloid 
drugs were tested in late-stage trials in 2001(79). RCTs during this time were substantially less 
burdensome for the participants with shorter trials of 3-6-month duration, less invasive 
investigations with no lumbar punctures, and only 2-3 MRI or CTs. 
 
 
Figure 1. Disease- Modifying Drugs tested in RCTs 2013. Modified from Lancet Neurology 2010. Mangialasche, 
Kivipelto et al. 
 
Development of new drugs takes many years and after preclinical research the clinical RCTs 
are described in three phases. Very few trials reach phase III. Most trials in phase I and II do 
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not show satisfying effect, but some trials had to be prematurely discontinued du to acceleration 
of deterioration in cognition or side effects such as elevated liver enzymes (80). 
 Phase I is when a new substance is first tested in a human being. Usually, the participants are 
healthy volunteers, but in some drugs with specific targets, the tests need to be performed in 
patients with a specific disease. The medical supervision is strict, and these trials are conducted 
in specialized medical units, phase I units. The trial's purpose is to determine whether the 
participants tolerate the drug and whether it behaves in the body in the manner indicated by the 
animal studies and other research. Patients with AD (including dementia) are often included in 
phase I trials.  
Phase II is usually the first time the drug is given to patients with the relevant disease. Different 
doses are tested to see how the drug affects the disease or its symptoms, determine the dose to 
be used in large-scale testing, and evaluate possible side effects. The number of patients 
recruited in Phase II trials is relatively limited.  
Phase III studies include a large number of patients, sometimes thousands, to assess efficacy, 
effectiveness, and safety. The large number is necessary to obtain a satisfactory basis for 
statistical analyses. (81, 82)  
In February 2020 there were 121 agents in ongoing clinical trials for AD therapy were 
registered in ClinicalTrials.gov, and 97 of them were classified as disease modification agents 
intended to change the underlying biology of Alzheimer's disease. In phase I, there were 27 
trials for AD therapy; 18 of these were DMT. Phase I trials had an average duration of 116 
weeks, including recruitment and treatment, and a mean number of 43 participants. There were 
73 phases II trials ongoing witch of 55 were DMTs. The mean treatment time was 43 weeks, 
with an average of 131 participants in each trial. Phase III trials included a mean of 554 
participants and had a mean treatment exposure of 64 weeks. DMT trials were longer and larger 
than symptomatic agents, with 98 weeks of treatment and including an average of 689 
participants. In February 2020, those trials required 31 314 participants (83).  
Study I was conducted with participants and their study partners included in early phase I- II 
pharmacological trials.  
3.2 E-HEALTH PREVENTION STUDIES 
One major future challenge is how to reach a large population with health-promoting 
interventions, and novel approaches are needed. Patient self-management has been suggested 
as a useful tool for CVD risk reduction. eHealth models can potentially increase adherence to 
therapy in CVD risk reduction, provide opportunities for individualized intervention strategies 
and serve as a platform for information and education (84, 85). Previous reviews show 
beneficial effects of coach-supported eHealth interventions on individual risk factors (86-88). 
The recent years' rapid development of eHealth for self-management has increased the 
opportunities for large-scale RTC in the area of lifestyle interventions targeting CVD risk 
factors and prevention of cognitive decline. E-health solutions may be a future way to reach 
lager population groups for dementia prevention. More knowledge is needed in RCT trials on 
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the effectiveness and feasibility of such solutions and qualitative data are needed on the 
preferences of the target groups. Study II and II investigated aspects of an eHealth solution. 
3.2.1 The HATICE trial 
The Healthy Aging Through Internet Counselling in the Elderly (HATICE) trial was an 18 
moth eHealth RCT conducted in Finland, France, and the Netherlands (23, 89). This trial 
recruited 2724 individuals aged over 65 years, without cognitive impairment, but with at least 
two vascular factors and/or CVD or diabetes. Participants in the intervention arm received 
access to the platform with advice on risk management and the possibility of interacting with 
a coach within the platform design. The control group had access to a platform with general 
health advice and no access to a coach. The primary outcome was a change in the composite 
score of three vascular risk factors. Other outcome measures were cognitive performance, 
changes in CVD risk and dementia based on risk scores, and CVD incidence. Both groups 
showed significant beneficial effects, but no difference in cognitive performance was reported 
(89). Sub studies described participants experiences of the HATICE trial (65, 71). 
Study II and III are embedded qualitative studies within the HATICE trial, conducted before 
and during the design (22) of the eHealth platform. 
3.3 NON-PHARMACOLOGICAL MULTIMODAL PREVENTIVE TRIALS 
Lifestyle related factors such as hypertension, diabetes, smoking, obesity, physical inactivity, 
depression, and low education, are attributed to one third of AD cases (90). Given the 
multifactorial etiology of AD, a multimodal intervention approach, targeting multiple risk 
factors are a promising prevention strategy. In Europe, several RCTs have been testing 
multimodal preventive interventions (4). The Multidomain Alzheimer Preventive Trial, MAPT 
(91), included 1680 individuals aged over 70 years with subjective memory impairment in a 
three-year multicenter study in France. Three groups received combinations of lifestyle 
interventions and a nutritional supplement, and a control group received placebo. The primary 
outcome was change in cognitive performance, but no significant differences were found 
between the groups. The Dutch Prevention of Dementia by Intensive Vascular Care, preDIVA 
(92) recruited 3526 participants without dementia aged 70-80 years from general practices. The 
intervention group received tailored lifestyle guidance and monitoring and treatment of 
vascular risk factors. The primary outcome was incidence of dementia. No difference was 
shown after six years. The Finnish FINGER trial (19) was the first multidomain lifestyle based 
RCT reporting that it is possible to prevent cognitive decline and impairment. The 2-year trial 
included 1260 participants at 6 study sites in Finland. Age range was 60-77 years. The 
participants did not show any significant cognitive impairment at inclusion, but they had an 
increased risk of cognitive decline based on the Cardiovascular Risk Factors, Aging and 
Dementia (CAIDE) Risk Score(49) and cognitive testing. Participants were randomized into 
an intervention and control group. The intervention group received: a) nutritional guidance 
according to national recommendations in Finland; b) physical exercise training in groups; c) 
cognitive training provided by a computer program; and d) monitoring and management of 
 
20 
vascular risk factors. The control group received regular health advice. The results showed an 
increase in overall cognitive functions. World-Wide FINGERS (WW-FINGERS) global RCT 
network (20) was launched in 2017. Multidomain lifestyle interventions for risk reduction in 
more than 30 countries will investigate feasibility and efficacy of the FINGER intervention 
model targeting vascular, metabolic and lifestyle factors. The network aims to harmonize and 
adapt multidomain intervention across various geographical, cultural, and economic stings and 
facilitate data sharing and analysis. 
Future possibilities for prevention in individuals with mild cognitive impairment, where 
targeting modifiable risk factors may not enough, might be a combination of disease modifying 
drugs and non-pharmacological interventions (20). 
3.3.1 The MIND-ADMINI trial 
The MIND-AD trial was a 6-month multinational parallel-group randomized controlled trial 
conducted in Finland, Sweden, France, and Germany. In Sweden, a 6-month extension was 
conducted. The study included in total 93 participants with prodromal AD using the 
International Working Group -1 criteria (IWG-1) (37). Other important inclusion criteria were 
vascular and lifestyle-related risk factors. Participants were randomized into three arms: a) 
multimodal lifestyle/vascular intervention; b) multimodal lifestyle/vascular intervention and 
medical food; and c) control or regular health advice/care. The primary outcome was feasibility 
and safety. Secondary outcomes were adherence to the individual intervention domains and 
healthy lifestyle changes. The multimodal lifestyle/vascular intervention included several 
components. 1) Nutritional guidance was delivered in 3-4 group sessions, and 3 individual face 
to face sessions with careful assessment of individual needs and providing individually tailored 
advice. Study partners were invited to participate in all visits. Recommendations were adapted 
to the respective national recommendations. 2) Physical exercise program was provided in 
groups of 4-6 participants twice a week. Physiotherapists or personal trainers led the groups.  
The exercise program was tailored to the participants' individual capacity. 3) Cognitive training 
included group sessions twice a week for about 20 minutes and the possibility to train using 
the computerized training program at home. A psychologist or occupational therapist led the 
group sessions. The web-based training program was in-house developed with an increasing 
level of difficulty. The program targeted executive functions, working memory, episodic 
memory, and mental speed. 4) Intensive management of metabolic and vascular risk factors  
was adapted to national guidelines. Additional meetings were scheduled with a study nurse to 
measure blood pressure, weight, BMI, hip and waist circumference, and further lifestyle 
management recommendations. If medication was necessary, the study physician wrote a 
prescription, or the participant was referred to regular health care. 5) Social activities were 
planned in connection to study visits. The arm with lifestyle/vascular intervention and medical 
food received also the study product Souvenaid, a 125 ml milk-based drink daily. In total 93 
participants were randomized. The study was completed in December 2019.  




4 GENERAL THEORETICAL PERSPECTIVES 
 
4.1 PERSON CENTEREDNESS 
Already Florence Nightingale described the importance of involving patients in the processes 
of care (93). Carl Rodgers introduced the term Person-Centered (PC) in the 1940th. The core of 
this theory is that each individual has several qualities and can draw strength from available 
resources and find way to remedy difficulties (94). Many followed,  and among those were 
well-known theorist, Dorothea Orem, who focused on person-centered care (95) and her theory 
is today implemented in care settings worldwide.  
A PC approach focuses on the biological, social, psychological, cultural and spiritual 
dimensions of a person (96), and a person centered care-  (PCC) means acknowledging the 
persons´ beliefs and values, the respect for the person, right to self-determination and mutual 
respect  as  the cornerstones (96). 
In regular health care, old routines and traditions and health care systems have not yet adapted 
to PCC, where focus is on the individual patient´s needs, preferences and values (97). 
Key components of a PC-approach are described by Ekman et.al (97) as a partnership between 
the person receiving care, their families, and health care professionals. This is not unlike the 
relationship between the researcher/study-team and the participant, including study partner in 
an RCT setting. Furthermore, Ekman describes that this partnership builds on mutual respect 
for each parties' knowledge about living with the disease, care, treatment, and rehabilitation.  
Person-centered care emphasizes the patients’ perspective and involvement, resulting in a shift 
from a model where patients are objects of care, to a model where they are involved as active 
partners in the decision-making process (98). For patients to be active participants in the 
decision-making process, they need to have sufficient and relevant knowledge, which can only 
be provided by continuous person-centered information. Patients’ needs and whishes need to 
be systematically assessed by health care professionals (99). In an RCT setting participants 
knowledge, need for information and decision-making processes are central for deciding to 
participate in a clinical trial, although these are seldom addressed.  
In an RCT context, applying a PC approach could mean  a more careful examination of the 
participants' motives for participating, including knowledge and awareness of the participants 
situation, previous experiences, fears, and stigma related issues, and addressing the differences 
in individual needs and expectations. 
The perspective of person-centeredness has not, to our knowledge, previously been used when 
discussing participants' situations in dementia prevention RCTs. During the work with this 
thesis, it became evident that both the theoretical and more practical perspectives of person-
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centeredness are constantly present in the findings of different studies. During the design and 
conduction of the studies, a general perspective of person-centered  frameworks such as the 
one presented by WHO 2007, People-centered health care: a policy framework (100) has been 
applied. 
In the Declaration of Helsinki (DoH), International Conference on Harmonization (IHC), and 
Good Clinical Practice (GCP) documents, people who are included in trials are referred to as 
study subjects. In the PCC the term patients is often replaced with the term person to shift focus 
from the disease to the person. In this thesis, the term participants is used.  Participating, in this 
context, mean taking part in a randomized controlled trial. 
4.2 DECLARATION OF HELSINKI 
Declaration of Helsinki (DoH) is a set of ethical principles developed by World Medical 
Association (WMA), regarding human experimentation and research on human material and 
data. It is regarded as the cornerstone document on human research ethics. The declaration was 
originally adopted in June 1964 in Helsinki, Finland, and has been revised several times, most 
recently in 2013. DoH addresses the informed consent as one of the basic principles. Another 
is that the investigator's duty is solely to the patient, and while there is always a need for 
research, the subject's welfare must always take precedence over the interests of science and 
society, and ethical considerations must always take precedence over laws and regulations. The 
declaration also addresses risks, burdens, and benefits. Vulnerable groups and individuals 
included in the research are discussed. The first paragraph states that the declaration is intended 
to be read as a whole and that all paragraphs are depended on each other, and a single paragraph 
should not be applied without consideration of all relevant paragraphs (101-103). 
The Belmont report from 1978, is another important document in the history of medical 
research ethics and is regarded as a landmark in the field. The Belmont report defines three 
important ethical principles in research on human subjects: 1) Respect for persons - individuals 
should be treated as autonomous agents; 2) Beneficence – a) do no harm; b) maximize possible 
benefits and minimize possible harm; and 3) Justice "Who ought to receive the benefits of 
research and bear its burdens?" - a) To each person an equal share, b) to each person according 
to individual need, and c) to each person according to individual effort.  
The Belmont report finally discusses these principles' applications and highlights three 
important elements in research with human subjects. 1) Informed Consent - the three 
components of the informed consent process are information, comprehension, and 
voluntariness; 2) Assessment of risks and benefits - the report discusses several aspects of risks 
and benefits, including when research includes vulnerable populations. The judgment includes 
the nature and degree of risk and the nature and level of the anticipated benefits; and 3) 
Selections of subjects - the selection of subjects should be fair to the individual and within the 
social context. Participation in potentially beneficial research should be fairly distributed. 
Research with potentially higher risk should not be offered only to less desirable subjects (104). 
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The fourths of the maim ethical principles for biomedical reseach; non-malefience, is not 
discussed in the Belmont report, but are an important principle in the DoH. 
Today the Belmont report is regarded as an important historical document that provides the 
moral framework for understanding the regulation on the use of humans in research in the 
United States(105, 106). 
4.2.1 Good Clinical Practice 
Good Clinical Practice (GCP) is an international quality standard that is provided by the 
International Conference on Harmonization (ICH). GCP defines a set of standards for clinical 
trials involving human subjects. GCP presents guidelines on the ethical aspects of clinical 
studies. The objectives of GCP are to safeguard the rights and wellbeing of the trial subjects 
and include protection of human rights for participants in clinical trials. GCP aims to ensure 
the credibility and accuracy of clinical data generated during clinical trials.   Furthermore, GCP 
aims to ensure that studies are scientifically authentic and that procedures are properly 
documented to assure the safety and efficacy of the new compounds (107).  
The tree first principles are regarded as the most important. 
1. Clinical trials shall be conducted in accordance with the ethical principles that have their 
origin in the Declaration of Helsinki and that are consistent with GCP and the applicable 
regulatory requirements. 
2. Foreseeable risks and inconvenience shall be weighed against the anticipated benefit to 
justify the risk. 
3. Rights, safety, and wellbeing of the subjects are the most important consideration and shall 
prevail over the interests of science and society. 
This thesis embraces the ethical principles described in the DoH and the studies are conducted 
according to the guidelines built on DoH. Knowledge generated in this thesis connects to 
several areas of the principles such as informed consent, risk/benefit, and to ensure the 





To face the challenges of recruitment for future trials, there is a need to know more about the 
individuals' motives for participating. To reduce dropouts and keep participants active and 
adherent in the trials, we need to listen to their experiences and understand how we can meet 
their expectations on trial participation in the best possible way. There is a need to understand 
what interventions are feasible for both participants and relatives/study partners across the AD 
continuum in lifestyle trials. New technology, such as internet platforms and eHealth models, 
will be increasingly used in research and the implementation of results, and thus, input from 
participants and end-users, will be crucial in this development. 
With substantial recent shifts in the dementia/AD field in clinical practice and research, 
changes have occurred in how clinical trials are performed and which target groups they now 
aim to include. A diversity of new questions has thus arisen. When studies become larger and 
are conducted internationally, protocols may need to be adapted to local settings. With local 
differences in social and health service systems, people from many different cultures, with 
different knowledge and understanding of disease and prevention, will be included in trials 
following a single main protocol. To facilitate this adaptation to local settings, increased 
understanding of the impact of cultural diversity regarding participants' attitudes and 
knowledge on prevention, disease, and research will be necessary.  
Ethical questions and decisions are frequently present in AD/dementia research. When shifting 
focus from patients with AD dementia to prodromal AD and across the AD continuum to 
preclinical non-symptomatic biomarker-positive and at-risk individuals, multiple ethical 
dilemmas arise. For example, if, when, and how information on biomarkers and dementia risk 
should be communicated in the best possible way, when used for inclusion in clinical trials. 
This knowledge will promote research and facilitate the implementation of research findings 
in clinical practice and society at large. Therefore, the main focus for this project is to illuminate 
different perspectives and experiences of  -dementia preventive clinical trials: pharmacological 
trials, lifestyle interventions, and usage of new technology, focusing on persons at risk for 
developing dementia, prodromal AD, and mild dementia in different settings, study partners, 





6 RESEARCH AIM 
6.1 GENERAL AIM 
The overall aim was to develop new knowledge regarding participation in clinical trials among 
study participants in the field of dementia prevention by exploring experiences of participation 
in dementia prevention clinical trials among study participants, study partners, and specialized 
personnel. Furthermore, the aim was to further understand their attitudes and knowledge about 
dementia and related diagnoses.  
6.2 SPECIFIC AIMS 
Study I 
To investigate practical experiences of staff, participants, and study-partners in 
immunotherapy RCTs. 
Study II 
To explore nurses' best practices with behavior change guidance for cardiovascular (CVD) 
prevention, including the potential for dementia prevention, in order to learn how to optimally 
integrate these into a coach-supported internet-platform. 
Study III 
This study aimed to explore knowledge of and attitudes towards prevention among older adults 
at risk of CVD and dementia, and to describe the facilitators and barriers for engagement in 
eHealth self-management prevention programs.  
 
Study IV 
To explore and describe the experiences of participation in the Multimodal preventive trial 







Qualitative methods are defined as a detailed investigation of a phenomenon through the 
collection of rich narrative materials, using flexible research approaches such as interviews, 
focus groups or observations (108).  
The goal for qualitative research is to generate knowledge that helps us understand the 
phenomenon as experienced by the participants themselves in their natural context (109, 
110). Qualitative studies are useful for studying new or complex phenomena that cannot be 
quantitatively measured. Qualitative methods involve systematically collecting and 
interpreting of data. In this project, the interviews gave the participants an opportunity to 
express their situation, experiences, and attitudes with focus on their needs and values. 
Individual interviews were conducted to capture the perspectives of the person and that 
person’s unique experiences, create meaning and create knowledge about the person´s 
context. Focus groups were used to increase the variety of perspectives when allowing the 
participants to interact and reflect upon others´ responses (111). A person-centered approach 
was applied during the project. The notion that there are several interpretations of the reality, 
influenced by the researcher’s knowledge, values and beliefs of the phenomenon, is the core 
of the constructivist paradigm (108), from which the point of view in this thesis is derived. 
7.1 QUALITATIVE METHODS STUDIES EMBEDDED IN RCTs 
As randomized controlled trials are getting more complex, there is increasing use of 
qualitative methods within RTCs to address a wide range of aspects. In an extensive 
systematic mapping review, O'Chathain describes the most common areas for qualitative 
studies within RCTs, the design, the measures used in the trial, the outcomes of the trial, and 
the target condition of the trial. The qualitative methods have been used in all stages in RCTs 
before, during the conduction of the trial, and after the trial. This review identified a number 
of potential values for using qualitative methods within RCTs, such as improving the external 
validity of trials by identifying barriers for recruitment, exploring contextual issues, and 
facilitating transferability important for implementation (112). 
7.2 GROUNDED THEORY 
Grounded Theory (GT) is a systematic method used to construct an explanatory model or 
theory about a phenomenon (113, 114) which is grounded in data that have been systematically 
collected and analyzed. GT was first developed by sociologist Glaser and Straus in 1967, 
California, USA (115). Strauss later modified his perspective on GT  in his work with Corbin 
(113, 114). Over time three different perspectives have emerged and are frequently used in the 
research area of health care. Glaser, Corbin and Strauss, and Charmaz methods have many 
similarities in method and terminology although there are several differences.  While Glaser’s 
classical GT-,  and even Strauss and Corbin´s, has its roots in a positivistic perspective, 
Charmaz introduced a constructivist perspective (116). Strauss and Corbin shifted to a more 
 
 27 
postpositivist position in their later work and Corbin acknowledged the co-construction of 
meaning between researcher and participants in the generation of data during unstructured 
interviews (117).  
GT is described as being useful in research areas where there is little previous knowledge, and 
where new perspectives might be beneficial (118). GT is also a suitable method when there is 
a process involved in the phenomenon under investigation, although process is not always a 
necessary  element to GT (116). 
In GT the data collection and the analyses occur simultaneously. The first step in the data 
analytic phase is coding of the data, where segments of data are preliminary sorted into similar 
categories. In the axial coding phase, the categories are brought together into groups or themes. 
The themes generally represent a new way of understanding the phenomenon investigated. In 
the selective coding, the researcher organizes and integrates the categories and theme in a way 
that represent an understanding or a theory (117). 
7.3 CONTENT ANALYSIS 
The first descriptions of qualitative content analyses related to a positivistic paradigm (119).  
The  content analysis method has over time, been developed from  a method of counting 
content, to a more interpretative method within the hermeneutic paradigm (120), characterized 
by multiple subjective realities (121). Content analysis is a systematic method to analyze 
qualitative data. This method can analyze manifest and descriptive content, resulting in 
categories and latent and interpretative content, resulting in themes (120, 122). The analytic 
process involves descriptions and interpretations of various levels of abstraction. No 
descriptions are free from interpretations (123). Content analysis can be performed in various 
ways, depending on the study aim, the quality of data and the knowledge and experience of the 
researcher, but the process of content analysis is characterized by de-contextualization and re-
contextualization. In the non-linear process, data are divided in to pieces meaning units, 
condensing and coding the units (120). In the re-contextualization phase, codes are sorted and 
compared by their similarities and differences and then abstracted into sub-categories. When 




Table 2. Overview of methods 
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7.4.1 Participants and settings 
7.4.2 Study I 
The study investigated experiences related to amyloid immunotherapy RCTs from the Clinical 
Trial Research Unit of the Memory Clinic at Karolinska University Hospital, Huddinge, 
Sweden. The Clinical Trial Research Unit carried out over 50 AD trials from 2001 and until 
the time of study I in 2011. During the period 2005 until the end of 2011, 14 amyloid 
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immunotherapy RCTs were carried out in the unit, including 154 participants. Eight trials were 
passive immunotherapy trials, of which 6 of this were phase I-II and 2 trials were phase III 
trial. A total of 90 participants were included. Three active immunotherapy trials in phase I-II 
included 64 participants. All trials are described in study I (124). Participants at the Clinical 
Trial Research Unit were recruited mainly from patients referred to the Memory Clinic for 
cognitive evaluation, but referrals from other memory clinics in Sweden were possible  
Staff Members in study I included, three physicians, one psychologist, and four research 
nurses at the Clinical Trial Research Unit. All staff members were experienced in clinical 
trials and had 4-15 years of trial experience. Two physicians and the psychologist worked 
part-time with patients referred to the Memory Clinic at Karolinska University Hospital for 
cognitive assessments. All research nurses worked full time at the unit. 
Patients with AD and study partners in study I were enrolled in Phase I/II amyloid 
immunotherapy RCTs at the Clinical Trial Research Unit. Twenty patients recruited as a 
consecutive sample and their caregivers who had been involved in phase I/II immunotherapy 
RCTs for up to one year were asked to participate in the study. This sample represented all 
participants meeting the criteria at that time. Nineteen patients, 9 women, and 10 men, were 
included. All 20 of the caregivers accepted participation. Patients' mean MMSE score was 23 
points at inclusion in the RCT and their mean age was 66 years. 
Amyloid immunotherapy RCTs trials were demanding for patients and caregivers. A visit 
could be as long as six hours, and caregivers had to be present at each visit. The RCTs' duration 
was 12-18 months and required in average 22 visits at the clinic. During that time, the 
participants took part in 8 evaluations of their cognition, 40-70 blood-samples were drawn, and 
10 EEGs, 2-3 lumbar punctures, 2-3 PET-scans, and up to 12 MRI investigations were 
performed.  
Studies II and III 
Study II and study III were part of the Healthy Ageing Through Internet Counselling in the 
Elderly (HATICE) study (ISRCTN48151589), a European randomised controlled trial that 
tested the efficacy of an eHealth multimodal intervention in a coach-supported internet 
platform for self-management risk factors for CVD and Dementia in older people to prevent 
CVD and cognitive decline. The HATICE study was conducted in Finland, the Netherlands, 
and France. Study II was conducted in Finland and the Netherlands. Study III was conducted 
in Finland, France, and the Netherlands. 
Study II and III were embedded in the HATICE study and were conducted in parallel with the 
development and design of the HATICE e-health platform, and several reports from the studies 
were delivered to the technical team to incorporate the results from the studies in the design. 
Study II participants 
 
Field experts recruited for Study II included Dutch primary care nurses, and Finnish 
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occupational healthcare nurses experienced in CVD preventive care. The places of 
recruitment were selected to find nurses experienced in prevention care, within the two 
countries´ health care systems.  
Fourteen nurses working in a semiprivate healthcare center in Kuopio (Eastern Finland) were 
invited by email and telephone. Six nurses (43%), all were female, consented to participate. 
Working as occupational health nurses, they cared mostly for patients of working age. Duration 
of clinical experience with CVD prevention ranged from 2 to 35 years. 
Thirty-two nurses experienced in CVD preventive care working in general practices in two 
urban areas in the centre of the Netherlands were invited by email and telephone. Seven female 
nurses (22%) agreed and gave their consent to participate. The participating Dutch nurses gave 
care services for patients of all ages. Duration of clinical experience with CVD prevention 
ranged from 3 to 11 years.  
The reasons for non-participation by Finnish and Dutch nurses was lack of time. 
Study III Participants 
Forty-four older adults at risk of CVD were recruited in Finland, France, and the Netherlands. 
In Finland, the participants were recruited from a previous trial cohort. In France and in the 
Netherlands, the participants were recruited from general practices.  
A simplified but comprehensive version of the HATICE trial criteria was used to identify a 
population as similar to the HATICE trial as possible: age over 65 years, basic internet literacy 
defined as the use of email, self-reported cardiovascular risk factors such as hypertension and 
dyslipidemia, active smoking, lack of physical exercise defined based on the WHO guidelines, 
self-reported history of CVD such as stroke/transient ischaemic attack, myocardial infarction, 
angina pectoris and/or peripheral arterial disease, and self-reported diagnosis of diabetes 
mellitus. 
Study IV 
This study was part of a larger project, the Multimodal preventive trial for Alzheimer disease 
(MIND-ADMINI) (ClinicalTrials.gov NCT03249688), a 6-month multinational, randomized 
controlled trial. The objective of MIND-ADMINI was to evaluate the feasibility of an adapted 
FINGER-based multimodal lifestyle intervention among individuals with prodromal AD, 
diagnosed using the International Working Group-1 criteria. Other inclusion criteria in the 
RCT were vascular and lifestyle-related risk factors. 
The MIND-ADMINI trial had three parallel arms: (i) multimodal lifestyle/vascular intervention, 
(ii) multimodal lifestyle/vascular intervention + medical food; and (iii) control. The lifestyle 
intervention consisted of the following main components: (i) nutritional guidance, (ii) physical 
exercise, (iii) cognitive training, (iv) social activity, as well as (v) monitoring of 
metabolic/vascular risk. The primary outcomes were feasibility and safety, and secondary 
outcomes were adherence to the interventions and lifestyle changes. 
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The MIND-ADMINI study was conducted in Sweden, Germany, France and Finland. 
Participants in study IV were recruited among participants from one of the Swedish study-sites 
at the Clinical Trial Research Unit of the Memory Clinic at Karolinska University Hospital, 
Huddinge, Sweden. Persons with prodromal AD who participated in MIND-ADMINI and 
provided consent-to-be-contacted forms, were provided information about the interview study 
and eight persons gave their informed consents and agreed to participate in the study. All 
interviews were conducted at the study-site at the Karolinska University Hospital. Mean age of 
Study IV participants was 66 years (range 62-75 years), 62.5% were female, mean MMSE 
score was 27 points, and mean formal education level was 14.5 years (range 9-18.5 years). 
Table3. Overview of participants 












Inclusion criteria Patients included in 
pharmacological 




in CVD prevention 
Purposive sample 
Similar to 
HATICE, age 65 
or older, basic 
internet literacy, 
self-reported CVD 
risk factors or 






Mean age (years) 66 48 72 66 
Cognitive status Mild AD dementia 
Mean MMSE =23 
(RCT participants) 
NA No known deficits 
At risk status 
Prodromal AD 
Mean MMSE=27 
7.4.3 Data collection and analysis 
Study I 
Questionnaires with open and structured questions were sent to 20 participants enrolled in 
phase I-II amyloid immunotherapy RCTs. Similar questionnaires were sent to their study-
partners. The questionnaire was designed to be easy to answer, even with mild AD dementia. 
Questions with graded answer alternatives and given answer alternatives were used. 19 
questionnaires from the participants were sent back and 20 from the study-partners. The 
results from the graded questions were summarized and presented in tables. Content analysis 
was used to analyse the answers as the method is suitable for a variety of data (125). Two 
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members of the group independently read all the text and selected meaning units that 
corresponded to the reseach question. The meaning units were condensed and coded. The 
codes and categories were thorough discussed in the research group and revised several times 
when going back and comparing the data (120, 122). 
Study II 
Two focus groups were conducted, one in the Netherlands and one in Finland. In both countries 
the focus groups were facilitated by experienced qualitative researchers and an assistant took 
detailed notes. A topic list was used to guide the discussion and the nurses could interact and 
respond to each other’s statements. After the first Dutch focus group, the topic list was refined, 
and some questions were added where more information was needed or for being clarification. 
In both countries experiences of working with CVD prevention were discussed, and in Finland 
the nurses were also asked about their experiences with prevention for dementia. The focus 
groups lasted for approximately 2 hours each. The discussions were audio recorded and 
transcribed.  -In Finland the transcriptions were translated into English since not all researchers 
were Finnish speaking. The analyses followed the principles of Grounded Theory (113, 114). 
In the Netherlands and in Finland 2 researchers coded the data and identified initial themes. 
Thereafter the codes and initial themes were compared and thorough discussed until consensus 
was reached. All data from Finland were then cross checked by the Finnish focus group 
moderator. At this point all Dutch themes and quotes were translated into English for further 
analysis. During the following iterative analysis phase, the data were compared and both teams 
returned to their data and the themes were merged and refined. The whole research team had 
two face to face meetings and multiple mail and phone conversations. The differences in the  
health care systems became evident during the analysis and therefor a description of both 
systems was developed and used to help the understanding during the analysis and in the 
presentation of the results. The results were returned to the participants for feedback. 
Study III 
Data were collected in three rounds of focus groups with a total of eight focus groups, three 
in Finland, three in the Netherlands and two in France. Semi- structured focus group 
interviews were conducted following an interview guide with the main topics described.  The 
interviews were conducted by experienced members of the local research team in the native 
language.  The interviews were audio recorded and detailed notes were taken. Two of the 
recordings, one in Finland and one in France failed due to technical issues, and the detailed 
notes were analysed. The remaining recordings were transcribed verbatim.   
Studies II and III were conducted according to grounded theory approach (113). The analysis 
followed the analytic steps of initial, focused, axial, and selective coding in an inductive and 
deductive approach. Constant comparison was used throughout by comparing data for 
similarities and differences. This process of comparison was extra important in the data sets 
from different countries throughout the whole analysis process.  Initially two researchers in 
each country identified codes and compared those before combined them in the axial-coding 
phase. This process was conducted in the local language within the local research team. In 
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Finland, where not all researchers were Finnish speaking, all data were translated into English. 
The translations were crosschecked by two researchers, fluent in both Finnish and English. 
When all the six first sessions were finished in the three countries, the findings were translated 
and combined in English. Numerous telephone meetings were held with the different research 
teams, as well as two face-to-face meetings.  
Study IV 
8 participants in the MIND-ADMINI  trial were interviewed twice, in the beginning of the study 
and after 6 months of participating in the trial resulting in 16 interviews in total. The 
interviews were divided between two researchers who each interviewed 8 participants. All 
interviews took place in the hospital facilities in connection to a planned MIND-AD 
intervention visit, according to the preference of the participants. A semi structured interview 
guide was used to ensure that the topics of the research questions were covered. All 
interviews were audio-recorded and transcribed verbatim. Content Analysis was used for the 
analysis (120, 122, 123). The transcriptions were read several times to get a fist sense of the 
data. This reading sometimes required relistening to the recordings to get an understanding of 
the text. Meaning units were identified. At this stage, a colour code was introduced to identify 
meaning units belonging to all the intervention components in the MIND-ADMINI trial and 
some meaning units concerning the logistics of the trial. These colour codes were then used 
in a later stage to sort the data according to different interventions components. The meaning 
units were condensed and coded. The codes were then sorted and compared on their 
similarities and their differences and sorted into categories that were further discussed in the 
research team. Although the data during the collection were presumed to be thin, they proved 
to be rich and allowed a higher degree of abstraction and interpretation of the whole dataset. 
The colour codes provided a possibility to describe more concrete pros and cons related to the 
participants´ experiences of the separate study-related intervention components. This way the 
colour codes became a way not to lose important content when all data were condensed and 
became more abstract. During the analysis, variation in the data was strived for. 
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Sweden 2011/1987-31/4. 43/03 
Study II  
Finland 35//2014     The Netherlands NL48261.018.14 
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Finland 35//2014     The Netherlands NL48261.018.14       France 2014/68 2014-A01287-40 





All studies followed and were guided by the DoH and the ethical principles for medical 
research.  
All participants received oral and written information about the study and had opportunity to 
ask questions to the researchers. All participants gave their own informed consent to 
participate.  
Participants in study I and IV were all included in an RCT. When informing the participants 
about the qualitative studies extra considerations were taken to address the risk of 
misunderstanding about the different studies. Additional and repeated information were 
provided to emphasize that their participation in the RCT would not be affected by taking part 
in the qualitative study. In Study I the participants answered the questionnaire anonymously to 
ensure that they could answer freely. In study IV the interviewing researchers were members 
of the RCT team with no/little direct involment in intervention activities, and interviews were 
decided to be the most suitable method for addressing the questions.  
All data are handled and stored according to regulations in Karolinska Institutet and the 
universities in the participating countries.  
 
8 FINDINGS 
8.1 STUDY I 
Staff members experienced in amyloid immunotherapy RCTs emphasized the high burden for 
the participants and their study-partners, often spouses or children, to participate in the trial. 
Especially demanding for the participants was the repeated cognitive testing, particularly when 
they experienced repeated failures. The staff members also discussed the written informed 
consent form as a struggle for the participants since it often was long, hard to understand, and 
demanded multiple signatures from the participants for separate study-related procedures. 
The participants' motives for participating in the RCTs were described as a strong wish to 
contribute to research and the hope of receiving an effective drug to cure or slow down the 
progression of the disease. Participants and their caregivers described that they felt safe and 
trusted that they would not be exposed to unnecessary risks during the trial. The caregivers 
worried about the possibility of receiving placebo while this did not seem to be a concern for 
the participants. Both caregivers and the participants described that they had received enough 
information about the trial, but they wanted more information about the disease and other 
treatment opportunities.  
Receiving professional support and regular health checks and the feelings of safety when being 
looked after by the study-team were mentioned as major advantages of participating, both by 
participants and study-partners. Participating in a trial also allowed meeting other people in a 
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similar situation, which was experienced as positive. Participants described few disadvantages 
while their study-partners stated that participation was time-consuming and burdensome for 
the participants, with pain and distress connected to some investigations.  
8.2 STUDY II 
The results are reported in two parts. The first part describes the nurses' experiences and 
practices with supporting the process of behaviour change for CVD prevention, including the 
potential for dementia prevention. The second part describes the nurses' suggestions on how to 
integrate their experiences in an online-support setting, stimulated by a demonstration of the 
HATICE platform. 
Part 1and Part 2 together identify three main themes that can be understood as the nurses' 
preconditions for effective behaviour change guidance in their patients:  
Establishing a relationship of trust  
Part 1: The nurses in Finland and the Netherlands emphasized that the key element of behaviour 
change support is in establishing a relationship of trust with the patient. This relationship 
develops over time when the person feels respected and comfortable enough to discuss lifestyle 
and behaviour issues. To personalize and tailor support to each individual’s needs facilitated 
the trusting relationship. Some differences between nurses in the two countries became evident 
in their preferences regarding the ideal mode of communication. The Dutch nurses expressed 
that repeated face-to-face contact was essential to establish a good relationship. The Finnish 
nurses experienced that an initial face-to-face contact could be sufficient to establish a 
relationship that could be followed up remotely. 
Part 2: When discussing the novel platform, the nurses regarded a coach as essential for 
optimizing personal support. An initial face-to-face consultation with the coach and the patient 
could strengthen the establishment of a good relationship. The Finnish nurses felt that online 
coaching could successfully establish a relationship of trust, provided that the coach was a real 
person, and regarded the online platform as a step forward in innovating healthcare. The Dutch 
nurses expressed more hesitance that the platform and coach cold substitute their personal 
guidance.  
Awareness and expectation management  
Part 1: To manage the patient’s awareness and expectations was described as a second 
precondition. In both countries (and especially in Finland due to a long-standing tradition of 
community-based CVD prevention), the nurses experienced that most patients had 
considerable knowledge of general CVD prevention but were less aware of their personal CVD 
risk status. To check the patients' level of knowledge and expectations regarding prevention 
and personal CVD risk were important steps in preventive work. The Finnish nurses 
acknowledged that CVD risk was also related to the potential for dementia prevention. They 
experienced that many patients feared dementia and lacked knowledge about the disease and 
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treatment and prevention options, creating a stigma towards dementia. The nurses were aware 
of the link between CVD and dementia but felt they lacked sufficient knowledge and training 
to provide proper support. 
2: In both countries, the nurses regarded the internet platform as a suitable means to raise 
awareness and increase health literacy. Furthermore, the nurses expressed the importance of 
managing expectations related to online support, as they expected that misunderstandings could 
arise more easily through this method.  
Appropriate timing and monitoring  
Part 1: To provide support at the right time was regarded as crucial by the nurses to support 
their patients’ lifestyle changes. Regular contacts and follow-ups promoted adherence and 
increased motivation. In both countries the nurses experienced that monitoring gave them 
opportunity to provide support when patients experienced obstacles or failures. The nurses put 
the patients in charge of preventive lifestyle changes and regarded their own role as supportive. 
However, the Dutch nurses preferred to have more control over the medical components of the 
prevention, for example, control of hypertension and diabetes, while the Finnish nurses 
regarded their patients as capable of staying in charge and described their own role as mentors. 
Part 2: In an online platform, the nurses speculated that the patient would be in charge of the 
timing of support and monitoring of progress. Even if the coach would have a reactive role, 
providing support would be in response to the patient's demand. However, the nurses felt the 
coach also needed to be proactive, for example when persons experience loss of motivation. 
This would require insight into people's activities on the platform. Both groups thought the 
platform should be aligned to regular healthcare.  
 
Figure1: Main themes and their preconditions. Differences and similarities between Finnish and Dutch nurses 
are shown to the left. Below is shown the impact of local healthcare practices. 
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8.3 STUDY III 
Three categories were identified, and a core category was developed, representing the attitudes 
of older adults at increased risk of CVD and dementia regarding engagement in eHealth self-
management prevention programs, and the facilitators and barriers.  
Access to reliable information about CVD and dementia  
In this study, the participants described that they experienced some confusion regarding 
prevention in general and even more concerning prevention of CVD and dementia. Participants 
in all three countries, Finland, the Netherlands, and France, expressed a need for reliable 
information about CVD and dementia and about how to put recommendations into practice. 
Superficial knowledge on prevention represented a significant barrier, and access to reliable 
information was regarded as essential for them to take steps towards prevention actions. Not 
being able to distinguish trustworthy from untrustworthy sources was identified as another 
barrier, especially concerning health-related information received from the Internet. The 
participants stressed that an eHealth platform could help provide trustworthy information from 
authorized sources tailored to individual needs. 
Trust in the healthcare provider  
The participants emphasized that trust in their primary healthcare providers, including their 
GPs and nurses, and trust in the received health-related information and the healthcare system 
is crucial to engage in prevention programs. In France and the Netherlands, the participants 
highlighted the importance of having a good relationship with their primary healthcare 
providers to engage in prevention programs, including those delivered through eHealth tools. 
They expressed a strong preference for an eHealth prevention program managed by their own 
primary healthcare provider. The Finnish participants acknowledged the role of trust in the 
eHealth lifestyle coach and data integrity when managing personal information as motivating 
factors to actively participate in eHealth prevention programs. 
The Finnish participants stressed the importance of their autonomy and own responsibility for 
their health and prevention, expressing their pronounced interest in health self-management.  
Dutch and French participants strongly relied on their GPs advice. 
Burden and stigma of dementia  
The participants compared the possibilities for prevention of CVD with those of dementia and 
described CVD as having good treatment options and a possibility to recover, compared with 
dementia as a condition with no possibility for recovery. Participants associated feelings of 
fear, shame, and hopelessness in anticipation of developing dementia with no available 
treatment. Dementia was described as a great burden caused by loss of one's independence due 
to loss of cognitive and physical capabilities and loss of social relationships. The participants 




Participants expressed a pessimistic attitude towards the prevention of dementia as opposed to 
CVD. However, being physically, cognitive, and socially active were described as potential 
preventive factors. The fact that dementia shares many risk factors with CVD was not generally 
known or expressed by the participants. The participants' scepticism towards prevention of 
dementia was closely linked to attribution of the role of genetic factors. 
The stigma connected with dementia was described by the Finnish participants as a barrier to 
obtaining reliable information, and that the fear of dementia made it more difficult to talk about 
and consult a doctor about it, compared with CVD. The participants at the same time described 
fear as an encouraging factor to engage more in the prevention of dementia than of CVD. 
From the three categories, a core category was developed: the interactive process of the three 
identified categories influencing engagement in the self-management prevention program.  
The three categories were interconnected through an interactive process and were strongly 
influenced by the local healthcare culture and context, which shaped them differently. To 
minimize the stigma, there is a need to receive relevant, reliable information and trust 
healthcare providers. However, the burden and stigma of dementia were described as a barrier 
to receiving reliable information and trusting healthcare providers.  
Figure 2. Presentation of the core category and the interactions between categories. 
8.4 STUDY IV 
 
The results of the study are presented in terms of a dynamic process, as demonstrated in Figure 
3. The results are presented as (i) Knowledge of Alzheimer's disease and prevention, (ii) 
Motives, (iii) Experiences of the received information, (iv) Decision-making, (v) Expectations, 
(vi) Experiences of participation in the MIND-ADMINI and (vii) Individual and external factors. 
Participants' knowledge about Alzheimer's disease and prevention, their motives to take part in 
the prevention trial, and their experiences of the received information regarding the prevention 
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trial led them to make the decision to take part in the trial and formulated their expectations. 
Several individual and external factors influenced participation in the study.  
Since the interviews were performed twice during the intervention period (i.e., in the beginning 
and the end), the results are presented as a dynamic process where the contents of the categories 
are developed during the participants' participation in the trial. The last phase in the process 
described participants' experiences of their participation in the prevention trial MIND-ADMINI. 
Motives for participating were altruistic with a high wish to help research. To be an active part 
in the trial was important for the participants. Other motives were related to personal benefits 
such as access to specialized health care and direct health benefits from the intervention. The 
participants’ belief in the intervention effect on the progression of their disease increased during 
the trial. The physical exercise component was the most appreciated, while being confronted 
with failures during cognitive training or testing were perceived as disadvantages of 
participating in the trial. 
The results show that the MIND-ADMINI trial was well tolerated by the participants. Although 
they early in the study experienced high burden with many visits at the study-centre, and 
difficulties with managing the extensive amount of information provided, they later in the study 












The overall aim for this thesis was to develop new knowledge regarding participation in clinical 
trials among study participants in the field of dementia prevention by exploring experiences of 
participation in dementia prevention clinical trials among study participants, study partners, 
and specialized personnel/staff. Furthermore, the aim was to further understand their attitudes 
and knowledge about dementia and related diagnoses and their experiences of participation in 
the dementia prevention clinical trials. 
In recent years, there has been a rapid development in dementia and AD prevention research. 
A shift to a more biological definition of the disease and acknowledging a life course 
perspective have led to the development of new diagnostic criteria and, new approaches when 
designing protocols, and the trials are targeting new populations (4, 18).   In this rapid 
development, it is essential to ensure that the basic ethical principles for medical research are 
followed. According to DoH (101), this responsibility is shared among all of those involved in 
a trial, local laws and regulations, and ethical committees, but also by researchers, physicians 
and study personnel, participants, and their representatives. The results in this thesis provide 
knowledge that is closely connected to several of the fundamental principles of research ethics 
described in the DoH, for example article 25 and 26 that discuss the informed consent. The 
participant has a right to be informed, but the researcher also has a responsibility to ensure that 
participants understand the given information. Study IV explored the understanding of the 
informed consent over time, which is highly relevant in long trials that include participants with 
cognitive decline. Several articles in the declaration discuss the risks, burdens, and benefits of 
study participation. In dementia prevention trials the risks, the burden of participation and the 
potential benefits of participation variety. To follow the DoH we need to evaluate and explore 
the participants attitudes and experiences and include this knowledge in future studies. 
The findings in this project highlight key topics that can be noted across the four studies as 
described below.  
Knowledge about dementia related diagnoses and prevention: 
The public knowledge about AD or other dementia related diagnoses, and the possibility for 
prevention have increased over time. However, the level of knowledge is still described as 
inadequate with several shortages. Knowledge is often limited to and highly dependent on 
personal experiences of the disease (71). In study III the participants confirmed the importance 
of personal experiences and describe how the fear of dementia made them take different 
actions. This fear could serve as a trigger to seek medical advice and initiate prevention 
strategies but could also prevent them from contacting medical health care and talk about their 
concerns. Lack of awareness about early symptoms and stigma can be barriers to early 
diagnosis (126). Experienced nurses working in prevention health care in study II identified 
public lack of knowledge about prevention, particularly the possibility of dementia prevention 
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in connection to CVD risk factors. They recognized themselves as educators in this matter but 
experienced a need for more information material and more education to be able to raise 
awareness among their patients. Even participants in study IV with the diagnosis of prodromal 
AD consider their knowledge about AD as low. A number of participants in study IV expressed 
a wish for getting more information, while others showed reluctance to learn more and 
expressed confusion on what diagnosis they had received. Prodromal AD is still mainly a 
research diagnosis and usually not commonly used in clinical practice, and it is unclear what 
information the participants had received in their regular care in the clinic. However, this makes 
it evident that the communication and information delivered to the patients must be clear and 
tailored to individual needs, especially when recruiting participants to clinical trials using 
research diagnostic criteria.  
The need and access to information: 
Patients and their caregivers need and actively seek information in relation to their diagnosis, 
(127, 128), and in study I and III this became evident when participants described the wish for 
information about the disease and treatment options, as a motive for participating in a clinical 
trial. Finding trustworthy information about AD, dementia and prevention was perceived as 
challenging by participants in this project, especially finding reliable information on the 
internet. Participants in study III particularly emphasized the challenge of evaluating the 
information and put trust in the publisher as a guarantee for quality. 
Patients and caregivers usually experienced a need for support after diagnosis. Advice, social 
and psychological support (129) and the  access to information needs to be continuous over 
time and adapted to different needs in time and format (126, 130). In study I and IV the 
participants pointed out that one of the advantages of participating in a clinical trial was the 
access to specialized staff at the study center.  
Understanding of provided information: 
Information provided, especially in clinical trials, may be perceived as hard to understand, 
especially for persons with cognitive deficits. Informed consent information is often long and 
perceived as complicated (70), which was confirmed in studies I and IV. Long and complicated 
information about the trial has also been described as a barrier for recruitment. Participants had 
questions about the key aspects of the trials. Previous literature has described it as a facilitator 
for recruitment of participants to clinical trials if research is embedded in patients' regular care 
with an established contact between clinicians and researchers (70). 
Medical decision-making capacity (MDC) is a person's ability to make decisions and choices 
in a medical context that aligns with one's values and preferences (45, 131). Cognitive abilities, 
such as understanding the related information, reasoning regarding risks and benefits, and 
ability to communicate wishes and decisions made are essential (45). 
The capacity to make one's own decisions is fundamental to the ethical principle of respect for 
autonomy and is a crucial component of informed consent to medical treatment and research 
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(101). Different terms are used in the literature to specify what type of medical decision the 
MCD refers to. Here, the concept MDC is used to describe participation in research and 
includes formulations such as "informed consent capacity" and research consent capacity (132). 
It is well described that MDC is affected and decreased in persons with cognitive impairment 
as they have a lower ability to evaluate, reason, and understand compared to healthy controls 
(133-135). A study examining the decisional capacity for participating in research found 
decreased MDC already in patients with MCI (136). In persons with early AD dementia, 
decreased MDC is well described (135, 137). 
In study IV, we specifically asked how the participants with prodromal AD understood the 
informed consent given information. At two time points the participants were asked to talk 
about the aim and the content of the study they had consented to participated in. A few weeks 
after the consent, the participants were able to give a reasonably good description of the study's 
aim. After six months of participating in the trial, they gave a vaguer description of the study's 
aim, and a few participants failed in describing the aim. Interestingly they perceived themselves 
as well informed and connected the given information to the trustful relationship with the study 
team. These results indicate the need to evaluate the understanding and MDC during lengthy 
studies to ensure that informed consent exists.  
The capacity to understand provided information is crucial for the participant to be able to give 
consent to participate in a clinical trial according to DoH, but is also necessary for the process 
of forming expectations on the participation in the trial. The expected probability for clinical 
benefits in early phases of pharmacological trials is low. However, unrealistic optimism for 
positive intervention effects in early phases of pharmacological trials has been previously 
described (138). Expectations on the burden of a lengthy trial with many visits and demanding 
interventions and risks and benefits are based on understanding the information provided. In 
an RCT, the participants receive many types of information that they need to manage. 
Researchers need to be aware of the individuals´ differences in their capacity to understand the 
provided information in the trial, to avoid misunderstandings and unrealistic expectations 
among the participants. 
Trust 
The frequent study visits built a trusting relationship with the study team, and the participants 
in study I expressed a feeling of being looked after. Trust was also evident in study IV; both 
studies were conducted in Sweden. In both trials, experienced personnel provided the 
participants with information, answered questions, and guided them to different support types 
tailored to individual needs.  
Participants' trust in the study team and the institutions that provide the studies contributes to  
the decision to participate in an trial (60). In study III the participants emphasized that the trust 
in healthcare personnel and in the information provided, and that trust influenced their actions 
towards participation in a prevention trial. The results in study III highlighted the importance 
of existing trust, but also indicated that trust is expressed differently in the three countries. In 
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study I, participants trusted that they were not being exposed to any unnecessary risks when 
receiving drugs tested in humans for the first time. They trusted the sponsoring companies, the 
ethics board's regulations, and the study team to keep them safe. Several times in the different 
studies, the participants referred to this trust as a safeguard when they could not understand 
given information or discuss risks and benefits. Also, in study IV, participants described how 
they could not remember essential parts of information about the study given in the informed 
consent, but they trusted the physician and considered themselves well informed. 
Consequently, this indicates that if participants state that they are is satisfied with the provided 
information, it does not necessarily mean that they have understood the information, and there 
is a need for caution especially if the information is intended for consent. In a recent review of 
qualitative studies exploring patients' perspectives on participating in clinical trials, trust was 
an identified theme describing patients' trust in staff, physicians, and institutions. Trust was 
important for the initial decision to participate as well as for the retention of the participants 
(97) and patients and their study-partners often described the importance of the fact that the 
study is university-led when deciding to participate (70). 
Stigma 
Fear of stigma in the population at risk, or in preclinical AD has been reported as relatively low 
(139), while other studies have highlighted that stigma in preclinical phases of the disease is 
connected to further cognitive decline and its consequences rather than to the label of the 
disease itself (140). Furthermore, low public knowledge about AD and dementia is a substantial 
contributing factor to the stigma surrounding this disease (71, 139, 141).  In study III the 
participants described that the fear of dementia made it harder to talk about the disease 
compared to CVD. The stigma also represented a barrier to obtain reliable information. In 
clinical trials, where repeated cognitive testing or cognitive training is a part of the protocol, 
the participants might be confronted with their personal shortcomings and become aware of 
further decline in their cognitive functions. In studies I and IV, the participants describe this as 
very stressful and one of the most pronounced disadvantages of participating in the trial. In 
trials with repeated cognitive testing and situations where participants risk being confronted 
with their cognitive decline symptoms, testing should be conducted with caution by well 
trained staff knowledgeable to meet the participants' reactions. Cognitive training in clinical 
trials should be designed to prevent participants from experience failure and self-stigma.  
Motives for participating in a dementia prevention trial 
Studies I and IV explored the participants’ motives for participation in dementia prevention 
trials. In study I, individuals with mild AD participated in early phase pharmacological trials. 
In study III, potential participants at risk for CVD and dementia were asked about their motives 
to participate in a hypothetical e-Health prevention trial, and in study IV, participants with 
prodromal AD in a multimodal prevention trial shared their motives for participation. The three 
trials represent different approaches to dementia prevention and target populations at different 
stages along the disease continuum, from at-risk populations to mild AD.  Interestingly, despite 
this difference, the participants in the trials presented similar motives for participating. 
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Altruistic motives were most pronounced in the participants that actually participated in trials. 
These participants were also further progressed in their disease. To help research and be a part 
of developing new knowledge, and hopefully new treatment possibilities were important for 
the participants. Many participants were concerned for their relatives and felt obligated to 
contribute in research in order to minimize the risk for their children or the next generation to 
suffer from the same condition. To contribute to research and help others have been indicated 
in an wider description of hope in early stages of AD (142). Several studies have investigated 
the motives of persons in the AD continuum for participating in clinical trials, but most studies 
have focused on investigating people's attitudes and interests in hypothetical trial situations.  
Altruism, and a willingness to help research, and the future generation, have been reported as 
some of the most important components to participating in clinical trials (61, 64, 143).  
Personal benefits were the other main theme of motives for participation. Although the 
interventions in the trials differed, the participants hoped that they could benefit from them to 
some extent. In study I, some participants expressed strong hope and belief in the drug to have 
an effect on the disease, although most of the participants and most study partners showed more 
realistic expectations on the effect of the drug. In study IV, the participants expected general 
health benefits from the intervention but initially expressed skepticism about the interventions 
effects on the disease. Interestingly their belief in the interventions potential effect on delaying 
the worsening of symptoms increased during the trial participation. Other personal benefits in 
common for the three trials were access to reliable information and specialized healthcare 
support.  The participant's motives for engaging in a dementia preventive trial were influenced 
by their previous knowledge and attitudes about dementia and prevention, the perceived trust 
in the healthcare provider, and the trust in the conductor of the trial. Fear and stigma could 
potentially hinder the participants from seeking health care and limit their access to clinical 
trials. These results were more nuanced in study III, probably because participants did not 
suffer from any significant cognitive decline and were not yet included in any trial. The 
knowledge of the participants motives for participating in a trial has been used and discussed 
in the context of recruitment strategies (62, 64-66, 68, 70, 144). However, the interaction with 
previous knowledge and the understanding of provided information should be acknowledged 
when discussing participants' decision to participate in trials. During the recruitment phase of 
the HATICE trial (23), a mixed-method study was conducted investigating the participants’ 
motives for participating. In a real-life setting, this study showed that the main reasons for 
persons to participate in the e-health prevention study were an interest in contributing to 
scientific knowledge and personal health benefits. The third reason for participation was access 
to additional medical monitoring. The study showed differences in how participants described 
their motives in the three countries in the trial, related to differences in the health care systems, 
the perceived access to care, and the trust in the GP’s recommendations (65). McCann 
described these findings as Conditional Altruism when participants initially tend to participate 
in a trial based on willingness to help others, but this unlikely to lead to further participation if 
there are no personal benefits (59). In study I, among participants who stated altruism as 
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motives for entering a trial, helping others gave them a sense of hope for future generations. 
Helping others as an expression of hope has been described earlier (142). 
Participating in a dementia prevention trial 
To participate in clinical trials has been described as demanding (58, 145). Pharmaceutical 
trials protocols allow very few deviations, and the total number of visits at the clinic might 
seem overwhelming. Many investigations such as MRI scans, CSF and blood samplings add 
to the effort, and early phase I and II drug trials are commonly associated with a potentially 
lower personal benefit and higher risk for side effects. Prevention trials targeting lifestyle 
factors may also be demanding. Several visits to the gym and regular attendance at different 
intervention activities and dietary changes may be challenging for the participants. Meanwhile, 
the personal benefits are regarded as high, and the risks are low. 
The fact that participation in AD trials is burdensome and requires study partners to accompany 
the participant to the study site and be willing to support and provide information, influences 
the potential participant's willingness to participate. The requirement of having a study partner 
is a barrier for participating in a lengthy trial as it is burdensome for family members or friends 
with frequent visits during working hours (68, 70). In study IV another aspect of the demand 
on a study partner was revealed. In studies that recruit person with prodromal AD, not all 
participants had informed their families or friend about their diagnosis, which complicated  the 
inclusion process as there were demands of a having a study partner to be able to participate in 
the trial. People do not always want to disclose their diagnosis to family or other networks 
(146) and this needs to be addressed in future trials. 
Although participants in studies I and IV emphasized that it was burdensome to participate in 
a clinical trial, they also felt that they had been given an opportunity. They described this as 
winning the lottery. The foremost perceived disadvantages of participating were that it was 
very time consuming and hindered them from other activities. Participants in pharmacologic 
trials also referred to extensive investigations with many invasive procedures such as lumbar 
punctures, repeated MRI scans and blood samples. In common for participants in 
pharmacological and lifestyle trials, were the negative experiences of repeated cognitive 
testing, or exposure to situations where they were confronted with cognitive difficulties and in 
worse cases, evidence of continuous loss of cognitive functions. In future trials, unnecessary 
testing should be avoided, and interventions should be delivered in a way that minimizes the 
participants’ risk of facing their cognitive shortcomings.  
There are many challenges in the design and conduction of dementia prevention trials: 
identifying the right participants, recruitment of large numbers of participants, retaining these 
participants, and keeping them adherent and engaged in the interventions.  
Identifying eligible participants for early dementia prevention trials is a major challenge (147, 
148) and biomarkers are becoming more important in clinical trials, both for selecting 
participants and assessing the efficacy and safety of novel treatments along the AD continuum 
(10). While inclusion based on biomarkers is becoming increasingly important in 
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pharmacological trials, the significance of biomarkers-based identification of participants in 
lifestyle intervention trials may less strict as these trials target multiple mechanisms of action 
(20). Studies reporting persons' attitudes on disclosure of biomarkers and risk factors for AD 
have been mainly conducted among persons with AD not participating in clinical trials or in 
healthy controls, who were asked to reflect upon a hypothetical situation (74, 75, 149). These 
studies suggest that the persons are interested in information about risk and biomarkers. The 
participants also emphasized the process in which risk information was disclosed and the need 
for information on individualized risk assessment, follow up and care. There is growing 
evidence that disclosure of genetic risk based on apolipoprotein E (APOE) genotyping to 
volunteer populations who are asymptomatic does not increase the risk for psychosocial harm 
(72). The perceived benefits of genetic testing are the possibility of advanced planning for the 
future, and the negative effect is often connected to how the results may affect family members 
(139).  To use different tools to estimate dementia risk is another strategy to select the right 
participants for prevention trials, mainly targeting lifestyle-factors. Several models have shown 
promising results (150).  
Recruitment of participants in clinical trials has been previously discussed in the literature. 
Successful recruitment of study participants is often based on factors of different variety (58, 
151). For example, Stormoen et al. showed that persons with AD dementia were more likely 
to participate in clinical trials with high risk than persons with mild cognitive impairment 
(MCI) or healthy controls. Stormoen et al. suggested that this might relate to the fact that 
persons with AD dementia may have a lower understanding of clinical trials' risk/benefit issues. 
Also, Nuno et al. suggested that there might be difficulties in recruiting participants in future 
trials focusing on preclinical or prodromal AD target groups since it becomes more common 
to include participants based on AD biomarkers, and the disclosure discussion has broadened. 
Several studies have explored people's expectations and experiences of such disclosures and 
discussed the consequences (149, 152-154). Study IV showed that the level of knowledge and 
previous experiences, the motives for participating and the participants understanding of the 
study related information are factors that influence the decision to participate. Even for the 
participants in a trial targeting prodromal AD where cognition is less affected, the situation and 
the information provided may be complex and hard to understand. 
Retaining participants in clinical trials is important to minimizing bias and error (155) and 
many different strategies are described in previous literature (69, 156). Those previous studies 
have focused on different strategies used and the number of used strategies by the trial-centres 
and seldom investigated the participants' preferences or needs. If the burden is too high, there 
is a risk that the participant gets too tired or does not engage fully in the intervention. Several 
studies have shown decreasing adherence to the interventions with increasing burden and 
complexity (157, 158). The cognitive difficulties that effect memory, attention, and decision 
processes are also barriers to the conduction of the trials (159). The findings in this project 
emphasize the importance of incorporating the preferences and the needs of the study 
participants in the stages of designing, conducting and evaluating clinical trials.  
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Applying a person-centered approach  
As personalized medicine becomes more and more important in dementia prevention research, 
there is a need for tailoring interventions according to an individual´s biological status. A 
person-centered approach describes the persons’ situation based on their history, their 
knowledge, preferences and their strength and weaknesses. In regular health care a person-
centered approach indicates a shift of focus from the disease to the person with strength, 
weaknesses, needs and preferences (97). In a RCT setting this could mean shift of focus from 
the participants as being passive study subject, to active participants and partners in the 
conduction of the trial.  
Person centeredness emphasizes the person´s perspective and active involvement in a decision-
making process. A prerequisite for the person to be able to be active in  this process , is access 
to sufficient ant relevant information (99). Other aspects of PC include that the person is 
listened to, and their knowledge, experiences and wishes are made visible. Person-centered 
care and three main principles for implementation are described by Ekman (97) (97) and has 
resulted in recommendations for implementation consisting of: 1) initiating the partnership, the 
patient’s narrative; 2) working the partnership, shared decision making; and 3) safeguarding 
the partnership, documenting the narrative. The findings in this research project suggest the 
potential benefits of adapting and implementing a structured model into the conduction of 
dementia preventive trials. 
Declaration of Helsinki in dementia prevention trials 
DoH described early ethical principles for research in human subjects. The document has 
continuously been updated to reflect contemporary research as clinical research has become 
more advanced and complex, and new knowledge has been developed, and these principles are 
today still very relevant. The declaration emphasize thar research is necessary to understand 
and develop knowledge on causes, development of diseases, and improve preventive, 
diagnostic and therapeutic interventions. The current existing interventions must be evaluated 
continually for effectiveness, accessibility, and safety. This statement supports the need to 
constantly evaluate ongoing research from the participants’ perspective to ensure and protect 
their health and rights according to the declaration. Many studies are conducted in a 
multinational research setting with a number of local regulations and laws. DoH still offers a 
framework across countries, in different cultures, healthcare, and political systems (104). Good 
Clinical Practice (GCP) is an international quality standard that is provided by the International 
Conference on Harmonization (ICH).This guidelines are used in the conduction of trials and 
all personnel in study-sites are regularly trained in GCP. The principles form DoH and PC, 
share many ethical standpoints and do exist side by side in most care settings. In a clinical trial 
setting, PCC needs clearly formulated guidelines to be put into practice.  
DoH and PCC both have their origins in fundamental ethical principles that guide and tell us 
why we do things in certain ways. Both require guidelines on how to complete tasks according 
to these principles. GCP provides strict guidelines for medical research. Many of this guideline 
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have served as foundations for national laws and regulations. European standards for PCC are 
under development. Patient involvement in healthcare – minimal requirements for person-
centered care (CEN450). PCC is often an accepted and sometimes required position in the 
health care systems where medical research is conducted. A structured PCC model, adapted 
for use in RCTs, could benefit participants on a personal level in ongoing RCTs and on a more 
strategic level to ensure quality and develop new research studies. 
With an understanding of the history of the development of medical research ethics, the failures 
the history presents, and knowledge about the fundamental documents that have led to today's 
guidelines and laws, we can also understand the need to continually evaluate and improve the 
safety and wellbeing of research participants (105, 160, 161). Today, in the times of a global 
pandemic, Covid-19, ethical questions regarding research on humans face new challenges. Old 
documents, such as the Belmond report with its fundamental ethical principles, are still referred 
to in discussing how to manage this new situation (162). Several of these principles are now 
regulated in laws, but ethical principles still have an important role in ensuring participants' 
rights and safety in rapidly advancing medical research. There is an urgent need from society 
to find solutions to handle the increasing cases of dementia worldwide, which propels the 
development and novelties in methods in the field of dementia prevention research. With 
understanding of the ethical background of the perspectives of DoH and a PCC, and developing 
frameworks for them to coexist in an RCT setting, could benefit research, patients on a group 
level and the situation for the individual participating in a trial.  
9.2 METHODOLOGICAL CONSIDERATIONS 
This project provides insights regarding on participation in dementia prevention trials, from the 
perspectives of participants, study partners and specialized personnel. The different studies 
included in the project were conducted within different types of prevention research such as 
pharmacological trials in early phase to multimodal lifestyle preventive trials, and trials that 
address the use of novel techniques as means of delivery of lifestyle prevention interventions. 
The trials targeted research populations in different stage along the Alzheimer’s disease 
continuum. 
An increasing number of embedded qualitative studies in RCTs have explored complex 
investigations from different perspectives, such as participants, study partners, and study 
personnel (112). In a review of qualitative research embedded in RCTs, O'Cathain described 
four common research areas: 1) Optimization of the content and delivery of interventions, 2) 
RCT design and conduct, 3) RCT outcomes, and 4) Target the condition or disease itself. 
According to the review, the research questions in these four areas focus on participants' 
experiences of different intervention components and their perceived benefits or the feasibility 
and acceptability of the intervention. Reasons for participation in a trial and adherence to the 
interventions and which outcomes the participants consider most important are other questions. 
Furthermore, qualitative studies embedded in RCTs are used to explore attitudes, beliefs, and 
experiences of the disease. Another important task for qualitative research is to identify local 
adaptions that could improve RCT conduct in a multinational setting (112). 
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Long complicated prevention trials are dependent on large enough numbers of participants 
wanting to participate. Dropouts are not only very expensive but also increase the risk of bias 
in the trial. Furthermore, the trials become more and more dependent on participants being 
compliant to the interventions. In lifestyle multimodal preventions trials this means that 
participants must make changes in their everyday life and really put an effort into the 
intervention. In pharmacological trials, the overall burden of participating in the trial, with 
many and invasive investigations has to be feasible in relation to the participants’ capacity. To 
be able to adapt the trials to participants’ conditions and wishes, there is an increasing use of 
qualitative studies in the design of new prevention trials (159). The literature supports the use 
of qualitative methods in the design of eHealth interventions. Input from end-users is valuable 
to make the product attractive and easy to use (163, 164) in order to keep the participants 
engaged. Study I and IV confirms the high burden of participating in the trials. Bothe the 
pharmacological trials and the multimodal prevention trial were perceived as time consuming. 
In the pharmacological trial the high burden was connected to discomfort during procedures 
and testing, while the prevention study demanded high engagement in the interventions with 
many visits in the study center.   
In study IV participants with prodromal AD were interviewed. There are several challenges 
with interviewing persons with AD. Even if their cognitive functions are expected to be largely 
unaffected, the participants were sometimes struggling with word finding, abstract reasoning 
and fluctuating awareness which have been described in early stages in the disease (165, 166). 
The participants were sometimes unable to stay on the topic of the conversation and repeatedly 
needed to be redirected by the interviewer. The researcher needs to be knowledgeable with 
these preconditions for communication and able to use strategies to minimize the distress for 
the participant, and to retrieve as high-quality data as possible. When analyzing the data, the 
transcriptions may at first seem thin, and demand multiple readings before the researcher can 
get a sense of the data as whole (167). 
In study I, participants were recruited from several ongoing pharmacologic trials; they were all 
recruited form one study site. This may have affected the results, which may have reflected the 
situation at this study site. Furthermore, the participants in this study were asked to answer a 
questionnaire. The open-ended questions were feasible for the participants to answer, but the 
questions with alternatives seemed to have caused some confusion and this needed to be taken 
into account when presenting the results. Even if some participants struggled with writing the 
answers on paper and some had help from relatives, the time to reflect and formulate answers 
seemed to be beneficial and the data was rich. 19 out of 20 participants answered the 
questionnaire and 20 out of 20 study partners, which might reflect the participants’ positive 
attitude towards research. Individual interviews might have been an even more suitable method 
to collect data, but in order for the participants to be able to answer the questions anonymously, 
the questionnaire was considered the most suitable method. As the participants would have 
easily been identified, and it was important that they felt safe to discuss freely, the anonymous 
questionnaire was a good choice. 
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Study II and III were conducted in a multinational setting. Participants and researchers came 
from 4 countries and were native speakers of 4 different languages, with English as a common 
work language. This was in some parts challenging and time demanding but was overcome 
with a rigorous planning and communication scheme. Data collection was performed in each 
country in the native language and initially analyzed within the local research group. In Finland, 
all data were translated into English as the researchers were not native Finnish speakers. 
Translations were cross-checked with the focus group leader who was native Finnish and fluent 
English speaking. Each country’s research team was trained and experienced in the area of 
research as well as the methods used. After each step in the process meetings were held within 
the larger international research group. Essential parts of data were translated into English for 
cross comparison. During this phase, all researchers from the different teams returned to their 
data and added, merged, and refined the themes until agreement was achieved. Although 
language barriers were a major challenge in this project and nuances in data might have been 
lost, a well-planned and structured research processes with high competence in research groups 
in each country and frequent meetings with all participating researchers ensured quality and 
minimized these risks. Furthermore, the frequent and intensive work with merging data 
facilitated methodological discussions and increased the understanding of the different health 
care contexts in the participating countries.  
Sample size in study II was limited, but the purposeful sampling resulted in rich data. In study 
III the large number of participants and the number of focus groups conducted, together with a 
thorough planning and collaborations within the large research group ensured trustworthiness. 
The large multi professional research group with broad experiences, the many discussions and 
the structured conduction of the project according to the chosen method, ensure 
trustworthiness. To conduct qualitative projects embedded in larger RCT studies entails even 
more challenges. All phases of the qualitative study have to be coordinated with the main time 
plan for the RCT. Study II and III were conducted during the design phase of the HATICE trial 
and all reporting had to be finished to be implemented in the final platform before the RCT 
study start. From a learning perspective, to be part of this process, study II and, to partly 
coordinate this work in a multidisciplinary, international setting were challenging, intense and 
rewarding with knowledge and experience beyond the scope of a doctoral education. 
The method for studies II and III, Grounded Theory, was chosen  based on its suitability for 
projects with limited previous knowledge, when studying processes (113, 116). The ambition 
was to follow the method according to Straus and Corbin (113), but as the project developed a 
more constructivist perspective influenced the work, with influences from Charmaz (116). As 
the project advanced, the frequent contacts between the research groups facilitated all the 
phases in project. Coding and analyses were thoroughly discussed in the group, ensuring a 
mutual understanding for the whole material. At the same time, these meetings helped 
overcome language barriers and facilitated the understanding of the differences in the contexts. 
In study III it became evident that one concept needed further exploration and a third round of 
focus groups were conducted. A theory is developed by a set of organized categories that are 
systematically integrated through statements of relationships that form the theoretical 
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framework explaining the phenomenon (113). Studies II and III did not aim to develop a theory 
alone but may contribute to theory development in the future together with knowledge from 
studies I, IV and future studies. Participating in dementia prevention clinical trials is, as a 
phenomenon, complex and further knowledge is needed to explain what, how, when, where 
and why of participating in trials and to develop an overarching explanatory concept.  
In studies I and IV content analysis was used. This method was decided to be relevant to meet 
the aims and describe the experiences of participants (study I, IV) and study-partners and 
specialized personnel (study I). In study II, 16 interviews resulted in 20 hours of recorded 
material and hundreds of pages transcribed material. The challenges with interviewing persons 
with cognitive deficits, discussed above, extended to the transcription parts of the study and 
continued in the analysis. To transcribe an interview with an impaired language is very 
demanding and takes a long time. In study II the person who did the interviews also performed 
the transcriptions, which was a considerable advantage. Knowledge about the context of the 
interviews was helpful to understand the content. Experiences in communication with persons 
having cognitive deficits facilitated the process of the interviews. In the first part of selecting 
meaning units and condensing them the quality of the language needed to be considered. With 
paying close intention in this phase of the analysis, the data proved to be richer than first 
assumed. The multi-professional research teams in studies I and IV were highly experienced 
in research and clinical work with patients and caregivers in the field of AD but also in the 
conduction of RTCs. Regular discussions during all of the phases in the studies ensured 
credibility in these studies. The findings in this thesis are all related to unique settings within 
different dementia prevention RTCs and reflect our current understanding. Transferability, 
with the possibility to extend these findings to other populations in other settings(108, 121), 
must be assessed by the reader, but the descriptions of the settings and participants in the 
different studies will support this process. Reflexivity was used in all projects, by discussion in 
the research groups and  using memos to reflect on philosophical standpoints, assumptions 
about the research, study design, codes and categories and the many procedural decisions taken 
during the analysis. Although memo writing is most used in GT, it is a helpful tool in all 
qualitative methods to develop thoughts, analytic skills, theoretical sensitivity and maintain an 
audit trail connected to the development of the project.  
Credibility refers to a systematic and rigorous field work, but also the systematic analysis of 
the data. Credibility also refers to the researcher’s knowledge and skills (111). The 
multidisciplinary research teams in the different studies represented a broad expertise in the 
research field as well as in qualitative research. U. Akenine is an experienced nurse with many 
years’ experience from working with dementia research, which of course may have influenced 
the results, but was essential in identifying the knowledge gaps and formulating the research 
questions, and an asset when analyzing the data. 
Finally, this project explored perspectives from active participants and potential participants 
and did not include persons that were willing to participate but were not eligible, or those who 
declined participation or participants who dropped out of a trial. Experiences and attitudes 
 
52 
about trial participation from these groups would be highly interesting, but outside the scope 
of this project. 
10 FUTURE DIRECTIONS 
The studies within this thesis have with the use of qualitative methods contributed with new 
knowledge and perspectives on participating in dementia prevention clinical trials. The results 
have already been used to evaluate and ensure quality in ongoing projects, to develop new 
platform or technologies, and have been part of a feasibility RCT. Many more trials with new 
technology and new interventions will follow. Future studies should focus on developing a 
model for gathering and evaluating different perspectives on participating in RCTs to ensure a 
development in the field and high quality RCTs, according to ethical principles of DoH.  
Future studies could focus on wider range of participants, those who were not eligible, non-
participants (if they give consent), and those who dropped out after inclusion in a clinical trial. 
This would give important insights about more general population and facilitate 
implementation of the results (eg lifestyle interventions, new technology) beyond clinical trials 
setting.  
Longitudinal qualitative studies are also needed to explore changes in motives, expectations, 
and experiences of participants in long trials. 
Further explorations of how the cultural and context differences affect participation will be 
essential in multinational trials. This is especially important given that many large-scale 
efficacy RCTs are multi-center, multi-national studies.  
Collecting user feedback and participants experiences using digital tools and new technology 
(e.g. E-FINGERS concept) is needed. New technology may facilitate individualized 
interventions and effective and sustainable implementation (especially important during and 
post-covid period), but user feedback and patient-public involvement (PPI) is central already 
early during the project.  
One important area is disclosure and communication of AD and AD risk status and involving 
patient in the decision process. Some ongoing projects (e.g. EURO-FINGERS consortium) will 
focus on these aspects. 
Finally, to develop a structured model to apply a more person-centered approach and 
incorporate this in studies and clinical setting is needed.  
New planned projects will use psychological interventions for patients with cognitive 
impairment to increase psychological wellbeing and flexibility which may also add adherence 
to multidomain lifestyle-based intervention (eg PIPCI trial). This will be increasingly important 
in future more complex trials combining multidomain lifestyle-based interventions and 




11 SVENSK SAMMANFATTNING 
Demenssjukdomar innebär en enorm global hälsoutmaning med en snabb ökning av antalet 
drabbade personer. Det finns ett akut behov av forskning för att hitta effektiva behandlingar 
och förebyggande strategier. Demensforskningen utvecklas snabbt där nya metoder och 
tekniker som används. Både farmakologiska och multimodala livsstils studier för 
demensprevention har blivit längre, mer komplexa och inkluderar personer tidigare i 
sjukdomsförloppet. För deltagarna i kliniska prövningar innebär detta nya utmaningar. 
Det övergripande syftet I detta projekt var att utforska erfarenheterna från deltagande i 
kliniska prövningar bland studiedeltagare, studiepartner och specialiserad personal.  
Dessutom var målet att ytterligare öka förståelsen om deras attityder och kunskap om demens 
och relaterade diagnoser. Alla studier använde kvalitativ metod. Data har samlats in från olika 
typer av randomiserade kliniska studier med hjälp av frågeformulär innehållande öppna 
frågor, fokusgrupper och individuella intervjuer. De använda metoderna är Content analysis 
och Grounded Theory. 
Studie I Frågeformulär med öppna frågor skickades till deltagarna i immunterapi RCT fas I-
II och studiepartners samt fokusgrupper genomfördes med specialiserad personal. Personalen 
betonade den höga bördan för deltagarna. Huvudmotiven för deltagande var en vilja att hjälpa 
forskningen. Fördelarna med deltagande var tillgång till specialvård. De största nackdelarna 
var att delta var tidskrävande och upplevt obehag i samband med vissa undersökningar. 
Studie II Fokusgruppsintervjuer hölls med expertsjuksköterskor (n= 13) inom CVD-
prevention Finland och i Nederländerna, för att beskriva sjuksköterskors erfarenheter och 
metoder för CVD-preventivt arbete, och att beskriva deras förslag på hur man integrerar 
dessa erfarenheter i en online e-häla plattform. Viktiga aspekter var att skapa en relation av 
förtroende, hantering av kunskap och förväntningar och monitorering i rätt tid. 
Studie III Fokusgrupper intervjuer genomfördes med äldre personer "i riskzonen" (förekomst 
av CVD-riskfaktorer) i Finland, Nederländerna och Frankrike som en del av HATICE 
projektet (n=44) om deras attityder till CVD och demens och engagemang i 
preventionsprogram via en e-hälsa plattform samt hindrande och underlättande faktorer. 
Resultaten prepresenterades i tre kategorier, tillgång till tillförlitlig information om CVD och 
demens, förtroende för vårdgivaren, börda och stigmatisering av demens. 
Studie IV Individuella intervjuer med deltagare i multimodal livsstils studie för 
demensprevention, MIND-ADMINI för deltagare med prodramal AD (n=8). Deltagarnas 
erfarenhet av att delta i studien presenteras som en dynamisk process. Tidigare kunskaper, 
deras motiv och den mottagna informationen styr deltagarnas beslut att delta. Studien 
tolererades väl, men deltagarna upplevde initialt hög börda och svårigheter att hantera den 
givna informationen i studien. 
Slutsatser: Motiven för att delta var altruistiska men också med hopp om personliga fördelar 
av interventionerna samt tillgång till specialiserad vård. Det finns skillnader i deltagarnas 
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preferenser och behov av stöd i en studie, dels i de deltagande länderna och i olika faser av 
sjukdomsutvecklingen. För att adressera detta, föreslås en mer personcentrerad metod 
applicerad i genomförandet av kliniska prövningar. Detta kan hjälpa till att förbättra 
situationen för deltagarna och höja kvalitén i studierna vilket är viktigt när studierna blir mer 
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